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Summary
The overall aims of the study were: to establish whether long saphenous veins from ischaemic limbs 
were more susceptible to developing intimai hyperplasia in organ culture compared with veins from 
non-ischaemic limbs; to investigate the effect of simvastatin on this process; to compare the 
proliferation and migration of vascular smooth muscle cells explanted from ischaemic and non- 
ischaemic veins and the effect of simvastatin on these processes; and to audit the outcomes of all 
infrainguinal vein bypass grafts performed at Glasgow Royal Infirmary between 1993-2003, 
correlating graft occlusion with statin use.
Veins were obtained from two patient groups: those undergoing lower limb amputation due to 
severe ischaemia- ischaemic veins; and those undergoing coronary artery bypass grafting using the 
long saphenous vein- non-ischaemic veins. These were placed in organ culture for 14 days in either 
culture medium with growth factors alone or culture medium with growth factors and simvastatin. 
At the end of this period, vein rings were fixed and processed for histological analysis and the area 
of Tunica Intima was calculated using Image Analysis software. Vascular smooth muscle cells were 
explanted from the vein rings and grown on for use in proliferation and migration assays. Cell 
proliferation was assayed using a labelled Thymidine incorporation technique. Cell migration 
was assayed using a modified Boyden chamber technique.
Veins from both ischaemic and non-ischaemic limbs had the same amount of vessel area as Tunica
Intima in the fresh fixed state. Veins from both groups showed significant growth of the intimai
layer following 14 days in culture. Veins from the ischaemic limbs developed significantly more
intimai growth compared with the veins from non-ischaemic limbs. Simvastatin abolished the
growth of intima in the veins from ischaemic limbs and reduced the growth of intima in veins from
non-ischaemic limbs. The proliferation of vascular smooth muscle cells from both ischaemic and
xii
non-ischaemic veins was inhibited in a dose-dependent manner by simvastatin. There was no 
difference in the mean 50% inhibitory concentration of simvastatin for the two groups of vein cells. 
Vascular smooth muscle cell migration in response to platelet-derived growth factor was enhanced 
in cells from the ischaemic veins compared with cells from the non-ischaemic veins. Simvastatin 
appeared to inhibit vascular smooth muscle cell migration.
Between 1993-2003, 207 infrainguinal vein bypass grafts were created in Glasgow Royal Infirmary. 
Data was available for 133 of these grafts. The graft patency in patients taking a statin at 1,3 and 5 
years was 97%, 91% and 83% compared with 88%, 72% and 56% for patients not taking a statin. 
The median survival of grafts was 9.8 years for those taking a statin and 6.7 years for those not 
taking a statin. These differences approach statistical significance. Additionally, female gender was 
associated with increased risk of graft occlusion.
In conclusion, ischaemia predisposes the long saphenous vein to develop intimai hyperplasia in 
organ culture and simvastatin abolishes this process. This tendency to develop intimai hyperplasia 
may be partly explained by the finding that vascular smooth muscle cells from ischaemic veins have 
an accelerated migration response in cell culture compared with cells from non-ischaemic veins. 
Simvastatin inhibits vascular smooth muscle cell proliferation and migration in vitro and this can 
explain the effect of simvastatin in organ culture. These findings raise the possibility of using 
simvastatin to prevent intimai hyperplasia in infrainguinal vein grafts. The concentration of 
simvastatin used in these experiments, however, was much higher than can be attained with normal 
oral doses and, as such, may lead to the development of novel drug delivery techniques such as drug 
eluting sutures. Clinically, simvastatin has been associated with improved infrainguinal graft 
patency. How this relates to the in vitro findings here is not clear but is likely to involve more than 
the known anti-proliferative and anti-migratory effects of statins.
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Chapter 1
INTRODUCTION
* ■ -'--.iv '.1.
1.1 Atherosclerosis
1.1.1 General aspects of atherosclerosis
Atherosclerosis is a multifactorial, chronic, systemic disease process which causes significant 
morbidity and mortality worldwide. The disease is known to begin in childhood with early changes 
to major hlood vessels having been identified during post-mortem examinations of young people. 
The process progresses gradually, however, and symptoms usually manifest clinically in middle age 
(1). The pathological lesion in atherosclerosis is the atherosclerotic plaque. These are lipid-rich areas 
within the vessel wall which are infiltrated by inflammatory monocytes and contain proliferating 
smooth muscle cells and fibroblasts as well as areas of collagen and lipid deposition. The presence 
of the atherosclerotic plaque reduces the luminal diameter of the affected vessel, thereby impairing 
the blood supply to the tissues supplied by that artery. Additionally, plaques are capped by a 
fibrocalcificic layer which, if breached, exposes the flowing blood to highly thrombogenic material 
and leads to thrombosis of the vessel. This can either reduce the luminal diameter of the vessel 
further or lead to complete vessel thrombosis and infarction of distal tissues. Clinically, this 
manifests as myocardial ischaemia if the coronary vessels are affected, cerebral ischaemia if the 
cerebral vessels are affected and lower limb ischaemia if the circulation to the lower limbs is 
affected. Most research into the process of atherosclerosis is in relation to cardiac and 
cerebrovascular disease. However, the same process is the cause of lower limb ischaemia.
1.1.2 Cellular Aspects of Atherosclerosis
Atherosclerosis is multifactorial. Processes which are known to be involved at a cellular level 
include endothelial dysfunction, infiltration of inflammatory cells, vascular smooth muscle cell 
(VSMC) proliferation and matrix and lipid deposition (2). Systemic risk factors for the development 
of atherosclerosis include hypertension, hyperlipidaemia, diabetes and smoking. These cause 
endothelial dysfunction which triggers a cascade of events resulting in the development of an 
atherosclerotic plaque. An established atherosclerotic plaque consists of an area of intimai 
thickening which is laden with lipid deposits both extracellularly and within foam cells, an intense 
inflammatory response with activated leukocytes and macrophages, and sheets of proliferating 
VSMCs. This is capped by a fibrocalcific plaque which may show signs of previous rupture and 
subsequent thrombus organisation.
1.1.2.1 Roie of the Endothelium
The endothelium plays a major role in the development of atherosclerosis. Damaged endothelial 
cells express adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular 
adhesion molecule-1 (VCAM-1), monocyte chemoattractant molecules (MCP-1) and E-selectin. 
These are important as they allow adhesion and migration of monocytes into the intima of the vessel 
(3;4) which then sets up a cascade of events resulting in the development of an atherosclerotic 
plaque. Additionally, damaged endothelium causes a lowering of the bioavailability of Nitric Oxide 
(NO). This may be through decreased secretion of NO or through increased NO inactivation via 
reactive oxygen species. NO is known to be involved in repression of cell proliferation by mhibiting 
upregulation of p21 and causing cell cycle arrest through blockade of cyclin A mRNA (5). As such.
the relative lack of NO in damaged endothelium contributes to the inflammatory process and allows 
VSMC activation and proliferation into the intima of the vessel.
1.1.2.2 Role of Monocytes
Monocytes are a type of circulating white blood cell which, upon stimulation, migrate out of the 
circulation through the vascular endothelium and differentiate into an activated form within the 
tissues. Once monocytes have migrated out of the circulation into tissues they are often termed 
macrophages. Monocyte migration into the intima of affected arteries is one of the earliest steps in 
the development of an atherosclerotic plaque. Stimulated by the presence of circulating lipoproteins, 
especially oxidised low density lipoprotein (LDL) which has been shown to be chemotactic for 
monocytes in vitro (6), monocytes adhere to endothelium and migrate into the intima. Subsequent 
phagocytosis of lipoproteins initiates the differentiation from monocytes into foam cells (7). There is 
evidence of foam cell accumulation in early atherosclerotic lesions found in children and young 
adults (1). Foam cells, unlike monocytes, are fixed within the tissue and will not migrate out. They 
represent an activated form of monocyte and, as such, generate an inflammatory cascade (8), 
releasing cytokines which, in turn stimulate the recruitment of more monocytes as well as 
stimulating the migration and proliferation of VSMC from the medial layer (9). Furthermore, 
monocytes secrete extracellular proteinases including collagenases and matrix metalloproteinases 
(MMPs) which serve to weaken and thin the surrounding fibrocalcific plaque (10) which may 
predispose to plaque rupture and subsequent vessel thrombosis.
1.1.2.3 Role of Vascular Smooth Muscle Cells
Migration and proliferation of VSMC into the intima is a predominant feature of atherosclerotic 
plaques. The VSMC are stimulated by both the endothelium and monocytes to migrate and 
proliferate. Cytokines and growth factors such as platelet-derived growth factor (PDGF), insulin-like 
growth factor-1 (ÏGF-1), epidermal growth factor (EGF) and Angiotensin II released from damaged 
endothelium, platelets and monocytes all contribute to the migration and proliferation of VSMC 
(2;3;5;8-10). The resultant effect of this process, along with the accumulation of monocytes laden 
with lipid, is a thickening of the intima which leads to luminal narrowing in the blood vessel. 
Furthermore, the VSMC appear to change from a contractile phenotype to a synthetic phenotype 
during this process (11). They subsequently secrete extracellular matrix which propagates the 
inflammatory response and may also contribute to the formation of the fibrous plaque on the surface 
of the lesion.
1,1.3 Consequences of Atherosclerosis
Impaired blood flow to any organ due to arterial luminal narrowing causes ischaemia. The end effect
of this process depends on the organ affected. For cardiac atherosclerosis, the result is angina or
myocardial infarction. In the case of cerebrovascular ischaemia, the consequence may be stroke or
multi-infarct dementia. When occlusive atherosclerosis affects the peripheral circulation, the most
commonly affected site is the lower limb. This process is most often felt as pain in the calf muscles
on walking (claudication). In some patients, however, the lack of oxygenated blood to the distal
tissues is so severe that necrosis develops. This is known as critical limb ischaemia (CEI) which,
without treatment, necessitates lower limb amputation. The major effective treatment for peripheral
arterial disease is arterial bypass grafting. This is normally performed using the long saphenous vein
5
and is most commonly in the form of a bypass graft from the common femoral artery to the popliteal 
artery. These grafts can restore a normal blood supply to the limb. Unfortunately, these grafts are 
susceptible to a process of narrowing which can lead to graft occlusion and recurrence of the 
ischaemic state of the limb. The process which leads to vein graft narrowing and occlusion is known 
as intimai hyperplasia and is the major focus of this thesis.
1.2 Lower Limb Ischaemia
1.2.1 Prevalence and Natural History
Chronic lower limb ischaemia secondary to atherosclerosis is a common disease worldwide. 
Accurately measuring the prevalence of the condition is difficult as many people have asymptomatic 
disease detectable only by physical examination which reveals reduced or absent peripheral pulses 
and or low ankle brachial pressure index (ABPI) (12). Based on epidemiological studies, the 
prevalence of lower limb ischaemia in Europe and North America is estimated at 16% of the adult 
population or 27 million people (13). The majority of these people (60%) are asymptomatic. Within 
the symptomatic population, the prevalence of disease increases with age to >20% in the over 80 age 
group (14). The Fontaine classification (Table 1) is routinely used to categorise severity of limb 
ischaemia.
Stage I Asymptomatic
Stage II Intermittent claudication
Stage III Rest pain
Stage IV Ulceration and / or gangrene
Table 1: Fontaine classification o f lower limb ischaemia.
The majority of patients with symptomatic lower limb ischaemia experience claudication. That is, 
they suffer calf or buttock pain on walking. The pain is relieved by rest and is reproducible at the 
same walking distance. Although other disease processes such as osteoarthritis can also cause leg 
pain on walking, intermittent claudication can be confirmed by measuring the ankle brachial
pressure index (ABPI) at rest and also after exercise. An ABPI of <0.95 at rest or following exercise 
confirms the presence of occlusive arterial disease affecting the lower limb and warrants further 
investigation and management. It is worth noting that certain disease states such as Diabetes 
Mellitus and Rheumatoid Arthritis can lead to calcification of vessels giving falsely elevated ABPI 
measurements. In these patients, a careful history and examination of the patient is of prime 
importance to reach the diagnosis. Intermittent claudication has a major impact on quality of life 
measures. Mobility scores are reduced, anxiety scores are increased and sleep, emotional behaviour 
and social interactions are affected (15). Additionally, between 3-8% of patients suffering from 
claudication (and 10% of claudicants over the age of 80 (12)) will experience disease progression to 
suffer pain at rest and / or gangrene with tissue ulceration. This progression of disease is classified 
as Fontaine Stages III and IV. These two stages of disease are termed critical limb ischaemia (CLI). 
There is no internationally agreed definition of critical limb ischaemia but one is that patients with 
persistent rest pain of over two weeks’ duration requiring regular analgesia and with an ankle 
pressure of less than 30mmHg or patients with ulceration or gangrene of the feet, again with the 
same reduction of ankle blood pressure would be classed as having CLI. The term critical limb 
ischaemia implies that the circulation has deteriorated to such an extent that, if uncorrected, there 
will be significant tissue loss and gangrene usually necessitating major amputation. Critical limb 
ischaemia causes severe pain necessitating opiate use which alters mental functioning and reduces 
quality of life (15). Additionally, chronic opiate use in other patient groups such as cancer patients, 
leads to malnutrition through appetite loss (16) and the same can be expected in patients with opiate 
use for critical limb ischaemia. A recent study showed the median time to being seen in a hospital 
outpatient clinic was 25 days for patients with critical ischaemia and that patients had experienced 
symptoms for a median of 8 weeks prior to this (17), giving more than enough time for significant 
alteration of quality of life.
Development of critical limb ischaemia necessitates urgent hospital admission for surgical 
assessment. If the patient is found to be suitable for intervention, they will undergo revascularisation 
using either a bypass graft or endovascular techniques. If neither of these are possible, the only other 
alternative is amputation. In 1997, a successful infrainguinal bypass graft was estimated to cost 
£4320 per patient, whereas the estimated cost of primary amputation was £12730. A failed bypass 
graft which then led to amputation was put at £17066 per patient (18). Other studies have found the 
same trend in costs for each procedure (19-21). Critical limb ischaemia is, therefore, a significant 
problem, both in terms of morbidity and mortality to patients, and in cost to society. In addition, as 
the average age of our population increases, peripheral arterial disease will continue to be a 
significant burden on health care resources.
Additionally, up to 30% of patients who undergo successful revascularisation for CLI will require 
amputation within 2 years of infrainguinal grafting due to graft occlusion (22). Graft occlusion 
within this time is mostly due to development of stenosed areas within the bypass graft caused by 
areas of intimai hyperplasia. The process of intimai hyperplasia is incompletely understood but the 
principal abnormality seen is thickening of the intimai layer with cellular proliferation and matrix 
deposition. This results in narrowing of the graft lumen which, if not corrected, leads to graft 
thrombosis and occlusion. Development of intimai hyperplasia within a graft is the major limiting 
factor in the success of bypass grafting and therapies aimed at preventing these stenoses could, 
therefore, be expected to improve the longevity of such bypass grafts.
1.2.2 Medical Treatment of Lower Limb Ischaemia
Medical treatment of lower limb ischaemia is primarily aimed at altering or halting the progression 
of systemic atherosclerosis, the underlying cause of arterial disease. Patients with peripheral 
vascular disease presenting with intermittent claudication have a threefold increased risk of death 
from cardiovascular disease when compared with age matched controls (23). 28% of patients 
presenting to a clinician with intermittent claudication will die within 5 years from cardiovascular 
causes (24). Medical management of peripheral arterial disease is principally aimed at altering this 
risk and includes antiplatelet therapy, smoking cessation, hypertension management, reduction of 
cholesterol levels and detection and management of diabetes. It is important to emphasise that 
patients with intermittent claudication (i.e. Fontaine Stage I & II) do not usually undergo surgical 
intervention and the medical management of these patients is of paramount importance. This 
contrasts with those patients suffering from critical limb ischaemia (i.e. Fontaine Stage III & IV) 
who must undergo surgical intervention if the limb is to be salvaged. In the latter group, the main 
purpose of medical management is to prevent cardiac or cerebrovascular events. Medical treatments, 
currently, cannot replace surgical management of critical limb ischaemia.
The Antithrombotic Trialists’ Collaboration showed that antiplatelet therapy reduced the incidence 
of any serious vascular event by 25% in patients with any manifestation of atherosclerotic disease 
(25). They also found a one third reduction in non fatal myocardial infarction, 25% reduction in 
non-fatal stroke and one sixth reduction in vascular mortality. Within the subgroup of patients with 
peripheral arterial disease, the reduction in serious vascular events was 23%. The most commonly 
used antiplatelet agent is aspirin but up to 20% of patients are intolerant of its gastro-intestinal side 
effects. Clopidogrel, a newer antiplatelet agent, is significantly more expensive than aspirin but has 
a better side effect profile. The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events
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(CAPRIE) study found a 10% reduction in serious vascular events in patients with a history of 
myocardial infarction, stroke or peripheral arterial disease treated with clopidogrel compared with 
aspirin (26).
Smoking is the strongest risk factor for the development and the progression of peripheral arterial 
disease. Therapies to help people give up smoking have, however, poor efficacy rates. In total, only 
10-15% of attempts to stop smoking are successful (27). Continued smoking in patients with 
peripheral arterial disease is associated with decreased survival and increased risk of developing 
critical limb ischaemia (28;29). Additionally, smokers have lower graft patency and survival rates 
after revascularisation when compared with non-smokers (30).
Antihypertensive therapy is associated with reduced risk of stroke, ischaemic heart disease and
vascular death (31). However, lowering of blood pressure in patients with peripheral arterial disease
may worsen symptoms. This is of particular concern with reference to p-blockers which may cause
additional peripheral vasoconstriction and thus, ischaemia. Despite this, a recent Cochrane
systematic review of the treatment of hypertension did not find any strong evidence that P-blockers
should not be used in peripheral arterial disease (32). Angiotensin converting enzyme inhibitors
(ACE inhibitors) have been shown to reduce cardiovascular morbidity and mortality in patients with
cardiovascular disease. The Heart Outcomes Prevention Evaluation (HOPE) study randomised
patients to ramipril lOmg or placebo. The treatment group showed a 22% reduction in myocardial
infarction, stroke or cardiovascular death in patients with left ventricular dysfunction and
hypertension (33). Additionally, there was a 25% reduction in cardiovascular morbidity and
mortality in those patients with peripheral arterial disease (34). The results of the European trial on
Reduction Of cardiac evens with Perindopril in patients with stable coronary Artery disease
(EUROPA) study strengthened the case for use of ACE inhibitors in established cardiovascular
disease. In this study, patients with chronic cardiovascular disease were randomised to perindopril
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8mg or placebo. After a mean follow up of 4.2 years, there was at 20% reduction in cardiovascular 
death, myocardial infarction or cardiac arrest in the treatment group (35).
Reduction in plasma cholesterol levels using statins (3-Hydroxy 3 methylglutaryl CoA reductase 
inhibitors) has been proven to reduce cardiovascular morbidity and mortality in patients with 
ischaemic heart disease and peripheral vascular disease (36-38). (See section 1.4.3). Three recent 
trials have shown various degrees of improvement in claudication in patients treated with statins 
(39-41). Aronow et al found an increase in mean walking time of 54 and 95 seconds before onset of 
claudication after treatment with simvastatin for 6 months and one year, respectively. However, the 
use of walking time before onset of claudication rather than walking distance makes this study 
difficult to interpret fully. Additionally, only 69 patients were enrolled in the study. Mohler et al 
randomised 354 patients and found an improvement in pain-free walking time in patients treated 
with 80mg atorvastatin compared with placebo but no difference in maximal walking time. Patients 
in the treatment group, however, did report an improvement in mobility scores assessed by the Low 
Level Physical Activity Recall (LOPAR) questionnaire but there was no difference in quality of life 
measures as assessed by the Short-Form 36 (SF36) questionnaire or walking function as assessed by 
the Walking Impairment Questionnaire (WIQ). Mondillo et al showed an improvement in pain-ftee 
walking distance and maximum walking distance of 90 and 126 metres respectively after 6 months 
treatment with simvastatin 40mg. The authors also found an increase in resting and post-exercise 
ABPI of 0.09 and 0.19 respectively in the treated group. In addition, sub-group analysis of the 
Scandinavian 4S study showed a reduction in the incidence of new-onset intermittent claudication in 
patients treated with simvastatin (42). Statins are the most commonly prescribed drugs for 
hypercholesterolaemia. Other cholesterol lowering agents include the fibrates which have proven 
beneficial effects especially with regard to lowering triglyceride levels and may be used with 
caution in combination with a statin (43). One of the fibrates, bezaftbrate has also been shown to
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reduce the severity of intermittent claudication in elderly men (44). Overall, the evidence suggests 
that cholesterol lowering treatment of patients with peripheral vascular disease does improve 
claudication to some extent.
Diabetes mellitus confers a more than 2-fold increase in the risk of developing peripheral arterial 
disease (45). The combination of peripheral arterial disease and diabetes puts patients at increased 
risk of cardiovascular events (46). Diabetic patients with intermittent claudication have an increased 
risk of disease progression to critical limb ischaemia (47). The multi-level nature of diabetic 
atherosclerotic disease means that revascularisation is less often possible and patients have a higher 
risk of amputation (48). Treatment of diabetes by maintaining tight glycaemic control reduces the 
risk of cardiovascular disease morbidity and mortality (49). For every 1% reduction in the 
glycosylated haemoglobin Ale level (HbAlc), a 21% reduction in all deaths related to diabetes has 
been shown. Additionally, there is a 14% reduction in risk of myocardial infarction and a 37% 
reduction in microvascular complications (50).
While these therapies are of proven benefit in reducing overall cardiovascular risk, none has been 
clearly shown to improve the symptoms of lower limb ischaemia, other than statins producing some 
mild improvement in intermittent claudication. Exercise programmes have been shown to increase 
the claudication distance (51) but this benefit is only seen in patients who follow supervised exercise 
programmes and the cost benefit is low (52). More recently, cilostazol (a phosphodieterase III 
inhibitor) has been introduced to the market and evidence suggests that claudication distances are 
increased on a par with exercise programmes (53;54). Overall, however, little can be done to treat 
the symptom of lower limb ischaemia medically and the majority of the treatment is aimed at halting 
systemic atherosclerosis progression and preventing secondary cardiac or cerebrovascular events.
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For patients with critical limb ischaemia, the only chance of returning the limb to a pain-free state is 
through surgical intervention.
1.2.3 Surgical Treatment of Lower Limb Ischaemia
Once critical ischaemia develops, the only surgical treatment options are revascularisation or 
amputation. Revascularisation may be in the form of angioplasty vdth or without stent insertion or 
bypass grafting. Before a decision can be made between these two options, the anatomical level of 
disease must be considered. Occlusive arterial disease occurring in the aorto-iliac segment can be 
successfully treated by either approach. Open surgery to bypass the aorto-iliac arterial tree using 
synthetic grafts such as Dacron or Polytetrafluoroethylene (PTFE) has good long term success rates 
(55;56). More recently, endovascular techniques to angioplasty and / or stent the suprainguinal 
vessels has been established as less invasive than open surgery and, in suitable lesions, is safe and 
effective (57;58)
Treatment of occlusive disease below the level of the inguinal ligament is different to that of aorto-
iliac disease. Here, angioplasty is recommended only for short (<3cm) focal arterial stenoses (Trans-
Atlantic Inter-Society Consensus (TASC) type A lesions) (59) as long term results of infrainguinal
angioplasty in critical limb ischaemia are not good. Angioplasty is, therefore, usually reserved for
patients whose medical condition precludes surgical bypass (60). Bypass surgery involves surgically
inserting a conduit, either synthetic or autogenous, from the patent artery proximal to the occlusion
to a patent artery distal to the occlusion. The technique of using autogenous vein to bypass an
occluded arterial segment in the lower limb was first performed in 1948 by Jean Kunlin. The same
technique was then applied in cardiac surgery after cardiopulmonary bypass became possible in the
1960s. In infrainguinal disease, the benefits from a successful bypass operation are immense. The
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lower limb can be saved and the patient restored to an almost pain free situation. The physical and 
mental benefits of this are great and quality of life is improved (61;62). Some studies, however, 
report an increase in anxiety scores following infrainguinal bypass (63) and that patient perceived 
benefits are greater than objectively measured mobility scores (64).
Infrainguinal bypass grafting is usually only performed for critical limb ischaemia and less often for 
patients with claudication. In the latter group, the benefits of infrainguinal bypass surgery are less 
clear. Although claudicants can have a very definite improvement in symptoms in the short term 
following infrainguinal bypass grafting, it is generally accepted that the risk of developing critical 
ischaemia when the graft eventually occludes is greater than if no bypass surgery had been 
performed. As such, infrainguinal bypass grafting is usually only performed for critical limb 
ischaemia. In claudicants with disease above the inguinal ligament, however, the role of 
revascularisation is clearer. These patients can often be treated by endovascular methods to relieve 
the arterial stenosis or occlusion or, in the case of more severe aorto-iliac disease, by open surgery. 
These interventions have improved outcomes when compared to interventions for infrainguinal 
disease (65).
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1.3 Bypass Grafting For Infrainguinal Disease
1.3.1 Conduit
The long saphenous vein is the most commonly used conduit for infrainguinal bypass surgery. It lies 
in an ideal anatomical location for use in lower limb bypass, running from the ankle to the groin 
making it long enough even for very distal grafting. The most common site of arterial occlusion in 
the lower limb is the superficial femoral artery in the thigh. Grafting to bypass this occlusion usually 
runs from the common femoral artery in the groin to the popliteal artery either above or below the 
knee joint level. Should the occlusion include the popliteal artery, the distal graft site can be 
extended to the tibial vessels. The vein may be used in 2 ways: either dissected out completely and 
its orientation reversed before anastomosis, or left in situ and valves destroyed by a valvulotome. In 
situ vein grafts were initially expected to be better than reversed vein grafts for several reasons. 
Firstly, the diameter match between the proximal and distal anastomoses is better, theoretically 
aiding the ease of the surgical procedure. Additionally, by not dissecting the vein out from all of its 
surrounding tissue, it was thought that the vein and nutrient vessels were preserved. However, the in 
situ technique requires valve disruption and this inevitably leads to endothelial damage. A few 
studies have compared reversed vein grafts with in situ vein grafts and no difference in graft patency 
or limb salvage has been shown. In some patients, the long saphenous vein is either unsuitable for 
grafting or has been removed previously. As a result of this problem synthetic alternatives Dacron 
and PTFE were introduced in the 1970s. These alternatives, however, have significantly poorer 
patency rates when compared to autogenous vein and are less resistant to infection (66;67),
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1.3.2 Graft Failure
Graft failure is a result of graft occlusion and can be divided into early, medium and long term 
failure. Early graft failure (within the first 4 weeks of surgery) is due to technical problems with the 
graft. Failure of grafts after this time but within the first 12-18 months is usually due to the 
development of areas of graft stenosis secondary to intimai hyperplasia. Late graft failure after 2 
years is most often due to progression of arterial disease either in the vessels proximal to the graft 
origin or in the distal vessels. Little can be done to avoid early or late graft failure but 80% of all 
graft failures occur between 1 and 18 months of surgery. As such, therapies aimed at preventing 
graft stenoses due to intimai hyperplasia can be expected to have a major impact in improving graft 
patency.
Patency rates of infrainguinal grafts depend on the distal anastomosis site and the graft material used 
(68;69). For above-knee popliteal artery bypass, the patency rate at 2 years is similar for autogenous 
vein and synthetic conduits at around 70-75%. For below-knee popliteal or tibial vessel bypass, the 
patency rates at 2 years are poorer - 70% for autogenous vein compared to 40% for synthetic grafts 
(67-69). If the graft does occlude, the conduit used is also of relevance. Occlusion of synthetic grafts 
more often leads to recurrence of critical ischaemia than autogenous vein graft occlusion (70). This 
is true regardless of the distal anastomosis site. One theory for this is that synthetic grafts are more 
likely to fail due to stenosis at the distal anastomosis which then leads to thrombosis and occlusion 
of the downstream vessels. In the case of vein grafts, however, the cause of occlusion is more often 
due to a mid-graft stenosis which does not then lead to distal thrombosis of vessels (67). Therefore, 
the long saphenous vein is the conduit of choice for infrainguinal revascularisation.
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In attempts to improve the patency of synthetic grafts, surgeons have attempted to improve the 
anastomotic site where the synthetic graft is joined to the native artery. Cuffs or patches of 
autogenous vein have been interposed between the synthetic material and the artery in various ways. 
The aim of these techniques is to reduce shear stress at the anastomosis site which reduces 
endothelial damage thus reducing intimai hyperplasia at the anastomosis leading to improved 
patency rates (71;72).
1.3.3 Graft Surveillance to Detect Stenoses
Vein graft stenoses develop in up to one third of infrainguinal bypasses, the majority of these 
occurring within one year of surgery (73;74), Detection of a critical stenosis by graft surveillance 
using duplex ultrasound allows for either endovascular or surgical correction of the problem. 
Without repair, these grafts would occlude and thrombose, potentially threatening the viability of the 
limb. The technique of graft surveillance and stenosis correction improves intermediate term 
patency of vein grafts but has not been shown to affect eventual limb salvage (74). Beyond the first 
year after surgery, the rate of developing a new graft stenosis is around 3% per year. Lifelong 
surveillance of vein grafts has been proposed but is currently not done routinely in the UK.
1.3.4 Vein Graft Stenosis Development
Autogenous vein transplanted into the arterial circulation as a bypass graft undergoes artérialisation, 
a process thought to be due to a combination of factors including higher flow rates and changes in 
wall pressures. The result of artérialisation is a thickening of the intimai layer with sparing of the
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medial and adventitial layers (75). Some veins, however, develop a more aggressive response to 
artérialisation and areas of focal luminal narrowing result. Such graft stenoses are due to intimai 
hyperplasia. The development of these stenoses is incompletely understood but is the major limiting 
factor in the success of both infrainguinal bypass grafts and cardiac bypass grafts. Many factors are 
thought to be involved in the process of vein graft stenosis, including endothelial dysfunction, 
VSMC migration and proliferation, vessel remodelling and matrix deposition. Additionally, it has 
been hypothesised that pre-existing vein abnormalities such as areas of existing stenosis may 
contribute to an accelerated process post-operatively (76). Other systemic factors which have been 
postulated as influencing vein graft stenosis rate are systemic factors such as diabetes, renal failure, 
homocysteine levels, fibrinogen levels and lipoprotein-(a) levels (77).
1.3.4.1 Cellular Processes Involved in Vein Graft Stenosis
The term intimai hyperplasia is used to describe the abnormal arterial response to injury such as 
balloon angioplasty and is also the term applied to stenotic lesions which develop in vein grafts. The 
process of intimai hyperplasia is similar to the atherosclerotic process: the principal abnormality 
seen is thickening of the intimai layer with cellular proliferation and matrix deposition (75;78). 
Lipid deposition and foam cell accumulation resembling atherosclerotic plaque has also been 
reported in stenotic coronary vein grafts (79;80). Additionally, remodelling of the medial and 
adventitial layers are seen with angiogenesis in these layers. The VSMC, endothelial cells and 
monocytes all play a significant role in intimai hyperplasia as discussed below.
The result of intimai hyperplasia in an autogenous vein bypass graft is significant intimai thickening, 
hypercellularity and marked matrix deposition. This results in luminal narrowing (81). Once this
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narrowing reaches a critical level, a vein graft stenosis will result in thrombosis and graft occlusion. 
The consequences of an occluded bypass graft depend on the degree of concomitant arterial disease 
but often results in a return of the critical ischaemia, necessitating amputation (70).
1.3.4.2 Role of Endothelium
Damage to the endothelium of autogenous vein graft is an inevitable consequence of the surgical 
procedure. Additionally, in reversed vein grafts, the shear forces associated with reversed flow 
direction and acute pressurisation by artérialisation of the vein are important (82). For in situ vein 
grafts, the disruption of valves by use of a valvulotome causes endothelial denudation. Furthermore, 
relative ischaemia of the vein wall by disturbance of the nutrient vessels (vasa vasorum) during 
dissection causes disturbance of the endothelial layer. Together, both stress and relative ischaemia 
cause a decrease in the availability of endothelial factors especially nitric oxide but also prostacyclin 
and adenosine (83). Loss of these factors promotes cell adhesion, cell migration and thrombosis in 
the vein by expressing adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), 
vascular adhesion molecule-1 (VCAM-1), monocyte chemoattractant molecules (MCP-1) and E- 
selectin (3;4). A biological relationship exists between replicating endothelial cells and smooth 
muscle cells. Replicating endothelial cells release factors that stimulate smooth muscle cell 
proliferation whereas confluent endothelial cells inhibit smooth muscle cell proliferation and 
migration. It can thus be expected that the disruption of the endothelial layer contributes to initiation 
of and propagates the process of intimai hyperplasia.
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1.3.4.3 Role of Vascular Smooth Muscle Cells
Vascular smooth muscle cells derived principally from the vein medial layer proliferate and migrate 
into the intimai layer (81). In doing so, they change from a contractile to a synthetic phenotype. 
Control of this phenotypic modification is poorly understood. Stenotic vein grafts show the highest 
level of cell proliferation in the tunica media where the majority of cells are VSMC. In the tunica 
intima, although the cell type is predominantly VSMC, the level of cellular proliferation is lower 
than that of the media and only one third of the proliferating cell type are VSMC (81). This suggests 
that VSMC proliferate and dedifferentiate whilst still within the tunica media and then migrate into 
the tunica intima where they are more involved with secretion of extracellular products. Stimuli for 
this response of VSMC include platelet-derived growth factor (PDGF), insulin-like growth factor-1 
(IGF-1), basic fibroblast growth factor (bFGF), plasminogen activators and cell-surface receptors.
1.3.4.4 Role of Monocytes
Within the intimai layer of stenotic vein grafts, monocytes account for the minority of cell types but 
represent one third of replicating cells (81). The exact role of monocytes in stenotic vein lesions is 
poorly understood. It is noted, however, that some vein grafts develop areas of intima laden with 
lipid rich proliferating foam cells similar to arterial atherosclerotic plaques (79). It is expected that 
these proliferating cells act in a similar fashion to those found in arterial atherosclerosis and secrete 
inflammatory cytokines which further propagate vascular smooth muscle cell proliferation and 
migration. However, a recent study showed an association between the number of foam cells in a 
vein graft stenosis and the degree of VSMC apoptosis (80). The authors suggest that the result of
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this VSMC apoptosis could weaken the intimai plaque and predispose to plaque rupture similar to 
that seen in arterial atherosclerotic lesions causing graft thrombosis.
1.3.4.5 Role of Extracellular Matrix
An event of prime importance in the migration and dedifferentiation of vascular smooth muscle cells 
is the secretion of extracellular matrix metalloproteinases (MMPs). These degrade the surrounding 
extracellular matrix, allow VSMC migration and promote VSMC proliferation. Vein graft stenoses 
are associated with increased levels of MMP-2 activation and MMP-9 secretion (84). Vascular 
smooth muscle cells, endothelial cells and monocytes have been shown to express these proteases. 
Regulation of these proteases is complex. Cytokines such as interleukin-1 alpha and growth factors 
(PDGF-BB) act to increase expression of MMP-9 in vein graft stenoses (85),
1.3.4.6 Role of Pre-existing Disease
It has long been suspected that pre-existing vein abnormalities such as areas of hypertrophy, 
sclerosis or calcification influence the outcome of vein bypass grafting (86;87). Other studies, 
however disagree with these findings (78;88-90). Recently, another study showed an association 
between hyperhomocysteinaemia, pre-existing vein hypertrophy and subsequent vein graft failure 
(77), Diabetes has also been implicated as a factor which is more likely to lead to vein graft failure 
through insulin stimulated VSMC proliferation (91;92).
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1.3.4.7 Role of Pre-Operative Tissue Ischaemia
One factor, which has not been investigated with respect to vein graft intimai hyperplasia, is the 
effect of pre-operative ischaemia. In critical limb ischaemia, there is profound tissue hypoxia which 
is often present for many months before revascularisation. The effect of ischaemia on the skin and 
subcutaneous tissue of the affected limb is clearly visible with areas of ulceration and / or gangrene. 
The nociceptive response to the profound ischaemia is equally prominent with patients requiring 24- 
hour opioid analgesia. Furthermore, small arterioles from distal muscle biopsies from amputated 
limbs show structural changes as well as functional changes including impairment of pressure 
dependent myogenic tone (93). It is possible, therefore, that profound tissue ischaemia also affects 
the long saphenous vein adversely. There may, therefore, be structural, functional or cellular 
changes within the vein which could influence the response of the long saphenous vein when used in 
bypass grafting.
This thesis aims to investigate the role of pre-operative ischaemia on the long saphenous vein and its 
propensity to develop intimai hyperplasia.
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1.4. Statins
1.4.1 Pharmacology of Statins
The statins are a group of drugs, developed for their cholesterol lowering properties. They exert their 
effect by inhibiting the intracellular enzyme 3-Hydroxy-3 methylglutaryl CoA (HMG-CoA) 
reductase, thus inhibiting the formation of mevalonate, a precursor in the intracellular synthesis of 
cholesterol. This decrease in available intracellular cholesterol stimulates the production of 
membrane LDL receptors, which pull cholesterol from the plasma, thereby reducing plasma 
cholesterol levels. The main site of action is in the liver.
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Figure 1: The mevalonic acid production pathway, the point o f action o f statins.
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First generation statins simvastatin, lovastatin and pravastatin are derived from fungal metabolites. 
Lovastatin is produced by the fungus Aspergillus terreus, simvastatin is obtained by replacing the 2~ 
methylbutyryl side chain with a 2,2-dimethylbutyryl group. Simvastatin and lovastatin are 
hydrophobic compounds whereas pravastatin is hydrophilic. Simvastatin is absorbed orally and 
activated by hydrolysation to its active form, simvastatin acid in vivo. Only 5% of orally 
administered simvastatin reaches the circulation in its active form, the majority being metabolised 
by first pass metabolism in the liver, its site of maximal action. Both simvastatin and lovastatin are 
metabolised by the cytochrome P450 enzyme system and care must be taken not to administer these 
drugs in patients who are also taking drugs which inhibit the cytochrome P450 system. When this 
occurs, the bioavailability of simvastatin and lovastatin can increase dramatically, possibly leading 
to significant side effects (94;95). Pravastatin, however, is not metabolised by the cytochrome P450 
pathway. The second generation statins atorvastatin, fluvastatin and cerivastatin are entirely 
synthetic compounds. They are all hydrophobic and metabolised principally by the cytochrome 
P450 system. Metabolites of both cerivastatin and atorvastatin also have HMG-CoA reductase 
inhibitive effects. Cerivastatin is an extremely potent HMG CoA reductase inhibitor, having 
equivalent cellular effects at concentrations 100-150 fold lower than the other statins. Cerivastatin, 
however, has been removed from the drug formulary due to a raised incidence of adverse effects, 
principally myotoxicity (94).
1.4.2 Side Effects of Statins
Overall, statins are well tolerated. The most common side effects are myalgia and raised 
transaminase levels. Less commonly, myopathy, myositis and rhabdomyolysis can occur, although 
these are usually related to enzyme deficiencies or concurrent therapy with cytochrome P450
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inhibitors. The exact mechanism of these skeletal muscle effects are poorly understood but since
, >.
mevalonate is also a precursor of products essential in the process of cell replication and 
glycoprotein synthesis it is possible that the cell membrane is disrupted, threatening the viability of 
the cell.
1.4.3 Cardiovascular Effects of Statins
The CARE study was similar, involving patients with known ischaemic heart disease but with 
cholesterol levels within the “normal range” (5.4 +/- 0.4 mM). Patients were randomised to 
pravastatin 40mg or placebo. Over 4000 patients were randomised and followed up for a median of 
5 years. The treatment group had reduced total and LDL-cholesterol levels of 20% and 28% 
respectively. The outcome measures of coronary death or non-fatal myocardial infarction were
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Beneficial cardiovascular effects have been shown to result from statin therapy. This is true for both |
secondary and primary prevention. The major studies showing a beneficial outcome in secondary 
prevention are the Scandinavian Simvastatin Survival (4S) study, the Cholesterol and Recurrent 
Events (CARE) study and the Heart Protection Study (HPS) (36-38).
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The 4S study looked at patients with proven ischaemic heart disease and raised cholesterol levels. 
4444 patients were randomised to either 40mg simvastatin or placebo and followed up over 5 years. 
In the treatment group, total cholesterol and LDL cholesterol were reduced by 25% and 35% 
respectively. Also, major cardiac events (coronary death, myocardial infarction or resuscitated 
cardiac arrest) were reduced in the treatment group (relative risk (RR) 0.66), there was also a 
reduction in coronary death (RR 0.58) as well as total mortality (RR 0.7).
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reduced by 24% in the treatment group. Also, the need for coronary revascularisation was reduced 
by 26% for coronary bypass and 23% for coronary angioplasty.
The Heart Protection Study enrolled over 20000 patients with a high risk of atherosclerotic disease, 
that is, prior history of coronary disease, non-coronary disease (cerebrovasculæ" or peripheral 
vascular) or diabetes. Patients were randomised to simvastatin 40mg or placebo regardless of 
baseline cholesterol levels. The treatment group showed a 24% reduction in all cause cardiovascular 
events, with a decreased rate of all cause mortality, principally due to an 18% reduction in cardiac 
mortality. There was also a significant reduction in vascular mortality as well as a 9% reduction in 
revascularisation procedures (coronary and non-coronary).
Taken together, these three studies demonstrate overwhelming benefit with statin therapy for 
patients with existing cardiovascular disease across all baseline levels of total and LDL-cholesterol.
Statins have also been shown to have beneficial cardiovascular effects in primary prevention, that is, 
in patients without a history of cardiovascular disease. Both the West of Scotland Coronary 
Prevention Study (WOSCOPS) and Air Force / Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) addressed this issue (96;97).
In WOSCOPS, 6595 men with raised cholesterol levels (mean 7.03mM +/- 0.57) but no prior history 
of cardiovascular disease, were randomly assigned to pravastatin 40mg or placebo. There was a 
reduction in total and LDL cholesterol of 20% and 25% in the treatment group as well as a 31% 
reduction in all coronary events, 32% reduction in cardiovascular mortality and a 37% reduction in 
revascularisation procedures.
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In the AFCAPS/TexCAPS study, 5608 men and 997 women with no history of cardiovascular 
disease were randomised to receive either lovastatin 20-40mg or placebo. Mean total cholesterol at 
the beginning of the study was 5.7mM. After a mean follow up of 5.2 years, there was a reduction in 
serum cholesterol levels (mean 3.96mM), as well as a reduction in first major coronary events (RR
0.63) in the treatment group. Additionally, there was a reduction in coronary revascularisation 
procedures (RR 0.67).
1.4.4 Anticipated Effects of Statins on Vein Grafts
Two recent publications have shown improved infrainguinal graft patency in patients being treated 
with statins (98;99). Both papers are retrospective reviews of patients undergoing infrainguinal 
bypass surgery. Henke et al investigated the drug history of 293 patients undergoing 338 
infrainguinal bypass grafts. The authors found that the majority of patients had co-existing 
cardiovascular disease (70% with hypertension, 52% with diabetes, 51% had ischaemic heart 
disease and 37% with hyperlipidaemia) but, despite this, prescription of cardioprotective 
medications was low. Only 56% of patients were prescribed a statin and 54% were prescribed an 
Angiotensin Converting Enzyme Inhibitor (ACE Inhibitor) despite national guidelines which 
recommend the use of these drugs in all patients with systemic atherosclerosis. The majority of 
patients (94%) were prescribed an antiplatelet agent or warfarin. At a mean follow up of 17 months, 
the authors found a positive correlation with graft patency and statin use (odds ratio (OR), 3.7) as 
well as a correlation with decreased amputation rate and statin use (OR, 0.34).
These findings are supported by the findings of Abbruzzese et al who analysed outcomes of 189 
infrainguinal bypass grafts on 172 patients with specific reference to statin prescription. Statin
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prescription was associated with increased secondary patency rate (97% +/-2% vs 87% +/- 4%) and 
the risk of graft failure was 3.2 fold higher in the untreated group. Neither of these papers sought to 
explain the mechanism of action of statins. However, both papers noted no significant difference in 
serum total cholesterol levels at the time of surgery between both groups (data only available in 47% 
of patients in the study by Abruzzesse et al), suggesting the effect is independent of cholesterol 
lowering. Possible mechanisms by which statins affect infi-ainguinal graft patency include 
endothelial effects, antiproliferative effects, extracellular matrix effects, anti-oxidant effects, anti­
inflammatory effects and anti-thrombotic effects.
1.4.5 Pleiotropic Effects of Statins
Not all of the effects of statins can be directly attributed to lowering of serum cholesterol levels 
(100;101). They have been shown to inhibit vascular smooth muscle cell proliferation as well as 
migration (102), activate endothelial NO release (103; 104), act as an antioxidant (105;106), reduce 
secretion of inflammatory cytokines (107; 108) and act as an antithrombotic agent (101; 109; 110). 
The combination of these effects is thought to be the means by which statins stabilise atherosclerotic 
plaques, contributing to their beneficial cardiovascular effects. Additionally, these cellular 
mechanisms are central to the development of intimai hyperplasia as discussed previously. As such, 
it could be anticipated that statins may also play a role in the prevention or attenuation of vein graft 
intimai hyperplasia. Other possible actions include interference with angiogenesis (111) and 
immune-modulation (112).
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1.4.5.1 Endothelial Effects
Endothelial dysfunction serves as a surrogate marker for cardiovascular disease (113). A measure of 
endothelial function can be made by assessing the vasoconstricting and vasodilating mechanisms of 
vessels. The most important mediator of vascular vasodilatation is nitric oxide (NO) and the most 
potent vasoconstrictors are endothelin-1 (ET-1) and angiotensin. By affecting the metabolism of 
these vasoactive mediators, statins enhance endothelial-dependent vasodilatation. Statins reduce the 
production of ET-1 from endothelial cells by down-regulating the production of pre-pro ET-1 
mRNA (114). Additionally, statins cause an increase in the local generation of NO from endothelial 
cells by increasing the half life of endothelial NO synthase (eNOS) (104;115).
Statin therapy has been shown to improve endothelial function in diabetic men (116). Patients had 
baseline measurements of brachial artery dilatation in response to ischaemia induced reactive 
hyperaemia. They were then were given oral cerivastatin for 3 days following which the test was 
repeated. There was a significant increase in the amount of brachial artery dilatation after only three 
days treatment but no further increase after continuation of cerivastatin treatment for three months. 
The effects seen at three days were in the absence of any change in serum cholesterol level, although 
a reduction in cholesterol was seen at three months. Another study investigated healthy males with 
normal cholesterol levels in a similar manner (117). This study found that oral atorvastatin caused 
an increase in forearm blood flow after four days. However, serum cholesterol levels were found to 
have fallen within two days of commencing oral atorvastatin. Cessation of atorvastatin treatment 
caused forearm blood flow measurements to return to normal after only one day, whereas 
cholesterol levels took twelve days to return to pre-treatment values.
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1.4.5.2 Antiproliferative Effects
The major antiproliferative effect of statins on VSMC is related to reduction in intracellular 
mevalonate production (102; 118). This substrate is a precursor of famesyl-pyrophosphate (FPP) and 
geranyl-geranyl-pyrophosphate (GGPP). Replacement of these compounds reverses the 
antiproliferative effects of statins. FPP and GGPP are isoprenoid compounds necessary for the post- 
translational prénylation of Ras, Rho and Rac. Without this post-translational modification, these 
small GTP-binding proteins cannot localise to the cell membrane (their point of action) and they 
cannot trigger other intracellular mechanisms required for proliferation and migration (119). By 
inhibiting cell proliferation and migration, statins can be expected to inhibit the development of 
intimai hyperplasia in vein grafts as these are two of the most important events within this process.
1.4.5.3 Extracellular Matrix Effects
Matrix metalloproteinases (MMPs) are secreted by VSMC and monocytes in the development of 
vein graft intimai hyperplasia (102; 120). MMP-9 secretion allows extracellular matrix degradation 
which potentiates VSMC migration and proliferation. By inhibiting MMP secretion, VSMC 
proliferation is inhibited. Statins have been shown to reduce secretion of MMP 9 in organ culture, 
causing a reduction in intimai hyperplasia (102; 121).
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1.4.5.4 Anti-oxidant Effects
By reducing the bioavailability of nitric oxide (NO), free radicals and reactive oxygen species 
contribute to endothelial dysfunction. Also, this reduction in the bioavailability of NO contributes to 
the increase in expression of chemoattractant molecules by endothelial cells which allow monocyte 
adhesion and migration into the intimai layer as well as promoting VSMC proliferation. 
Furthermore, oxidation of LDL-cholesterol plays a pivotal role in the pathogenesis of 
atherosclerosis.
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NAD(P)H oxidase is expressed at increased levels in balloon injured arteries and in atherosclerotic 
vessels (122; 123). It has also been identified within dedifferentiated VSMC in neointimal lesions of 
aortocoronary vein grafts (124). The result of increased levels of NAD(P)H oxidase is an increase in 
free radical formation and NO inactivation. Statins have been shown to interfere with the function of 
NAD(P)H oxidase (125) creating antioxidant effects. Additionally, these antioxidant properties of 
statins would be expected to reduce oxidised-LDL levels and enhance endothelial NO 
bioavailability. Together, these would contribute to attenuating intimai hyperplasia in vein grafts.
1.4.5.5 Anti-inflammatory Effects
1.4.5.6 Anti-thrombotic Effects
By inhibiting platelet aggregation and improving platelet function through increased NO 
bioavailability and thromboxane A2 inhibition (119), statins exert an anti-thrombotic effect. 
Furthermore, tissue factor (TF) expression by monocytes, endothelial cells and VSMC has been 
shown to be reduced by statins, further contributing to their anti-thrombotic role (109;126). These 
combined anti-thrombotic effects could be expected to reduce the risk of vein graft thrombosis and 
contribute to the beneficial effects of statins.
I
Statins have been shown to reduce the production of pro-inflammatory cytokines including 
Interleukin-1 (IL-1), tumour necrosis factor alpha (TNFa), Interleukin-6 (IL-6) and cyclo- 
oxygenase-2 (COX-2) from endothelial cells, VSMCs and leukocytes (107;108). These effects may 
result in reduced adhesion molecule expression such as ICAM-1, VCAM-1 and reduced leukocyte 
activation. Together these effects would be expected to attenuate the process of vein graft intimai 
hyperplasia. ;
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1.5. Overall Summary & Aims of the Project
■I
Intimai hyperplasia closely resembles the process of atherosclerosis, with VSMC migration and 
proliferation, intimai thickening and extracellular matrix deposition. Intimai hyperplasia leads to 
significant stenoses in one third of infrainguinal vein grafts within the first year of surgery and is the 'I
4
major limiting fector in the success of bypass grafting using the long saphenous vein. Patients
'4
undergoing lower limb bypass surgery have profound tissue ischaemia affecting the skin,
4subcutaneous tissue, small arterioles and nociceptors. Ischaemia may also adversely affect the long Isaphenous vein before it is used as a bypass graft.
Statins (3-Hydroxy 3-methylglutaryl CoA reductase inhibitors) have well established 
cardioprotective effects related to cholesterol lowering. They have also been shown to have many 
other (pleiotropic) effects including improved endothelial function and inhibition of VSMC 
proliferation and migration. More recently, statin therapy has been associated with improved 
patency rates of infrainguinal bypasses.
Project Aims:
1. Compare the susceptibility of human saphenous vein to develop intimai hyperplasia in organ 
culture between two groups: Ischaemic and Non-Ischaemic Veins, and to investigate the effect of 
simvastatin on this process.
2. To determine the effects of simvastatin on vascular smooth muscle cell proliferation on cells 
explanted from the two groups of veins: Ischaemic and Non-Ischaemic.
3. To determine the effects of simvastatin on vascular smooth muscle cell migration on cells 
explanted from the two groups of veins: Ischaemic and Non-Ischaemic.
4. Perform a retrospective analysis of all infrainguinal bypass grafts performed at Glasgow Royal 
Infimiary between 1993 and 2003 and to correlate outcome with statin therapy.
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Chapter 2
MATERIALS AND METHODS
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2.1. Ethical Approval
Ethical approval was sought and obtained from the North Glasgow Hospitals NHS Trust Research 
Ethics Committee. Authorisation was obtained to approach patients to obtain consent for removing a 
portion of long saphenous vein for use in this study. The patient groups to be included were those 
undergoing lower limb amputation and those undergoing coronary artery bypass grafting. Informed 
consent was obtained from all patients involved in the study.
2.2 Patient Groups and Tissue Collection
2.2.1 Patients Undergoing Amputation
Patients were identified as being suitable for inclusion in the study by Consultant Vascular Surgeons 
at Glasgow Royal Infirmary and Gartnavel General Hospital. All patients were scheduled to undergo 
lower limb amputation due to ischaemia from chronic peripheral vascular disease. Patients were 
deemed suitable for inclusion if they met the criteria in Table 2 below. Consent was obtained to 
remove the long saphenous vein from the amputated lower limb after amputation had been 
performed.
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Inclusion Criteria Exclusion Criteria
Age All ages
Sex Both genders
Aetiology Ischaemia
Combined ischaemia / 
infection
Infection alone 
Absence of ischaemia
Amputation Type Primary Above or Below 
Knee Amputation
Minor Amputation 
Revision of Amputation
Mental State Unable to give informed 
consent
Table 2: Inclusion & exclusion criteria for enrolling patients undergoing amputation.
2.2.2 Patients Undergoing Coronary Artery Bypass Grafting
All patients in this group were due to undergo aorto-coronary bypass grafting in Glasgow Royal 
Infirmary. Patients were identified as being suitable for inclusion in the study by the primary 
investigator. Patients were deemed suitable for inclusion if they met the criteria detailed in Table 3 
below. Consent was obtained for the primary investigator to be given any leftover portion of long 
saphenous vein not required for the bypass grafting.
Inclusion Criteria Exclusion Criteria
Peripheral Circulation Palpable pedal pulses ABPI <=0.85
Previous Vascular Surgery
Gender Both
Age All
Mental State Unable to give informed 
consent
Table 3: Inclusion & exclusion criteria for enrolling patients undergoing coronary artery bypass 
grafting.
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2.2.3 Collection of Tissue from Ischaemic Limbs
After amputation, the lower limb was placed on a sterile drape on a theatre trolley. This was taken to 
a side room off theatre where the long saphenous vein was identified and dissected out along with its 
surrounding subcutaneous tissue. This was placed in sterile culture medium (50:50 mix of 
Waymouth’s Medium and F12 Ham with 1% Penicillin/Streptomycin solution) and transported back 
to the laboratory at the University of Strathclyde at 4^C.
2.2.4 Collection of Tissue from Non-Ischaemic Limbs
After coronary artery bypass grafting was completed, any leftover long saphenous vein was placed 
in sterile saline solution at 4^C. The primary investigator was telephoned by theatre staff to collect 
the vein. The vein was transferred to sterile culture medium (50:50 mix of Waymouth’s Medium 
and F12 Ham with 1% Penicillin/Streptomycin solution) and transported back to the laboratory at 
the University of Strathclyde.
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2.3. Organ Culture
The long saphenous vein was dissected out from its surrounding tissue in a sterile culture hood 
(Class 2) in the laboratory. Following this, the vein was cut into 2-4mm rings using a sterile scalpel. 
Each ring was numbered sequentially. Rings 1,4,7,10, 13 and 16 were fixed immediately in 10% 
formal saline. Rings 2,5,8,11,14 and 17 were placed in wells of a 6 well culture plate (Coming) 
along with culture medium (50:50 mix of Waymouth’s Medium and F12 Ham with 1% 
Penicillin/Streptomycin solution) containing 15% Foetal Calf Serum and simvastatin at 5pM. Rings 
3,6,9,12,15 and 18 were placed in wells of a 6 well culture plate along with culture medium (50:50 
mix of Waymouth’s Medium and F12 Ham with 1% Penicillin/Streptomycin solution) containing 
15% Foetal Calf Serum and equal volume of vehicle (Sodium Hydroxide/ Ethanol solution) used to 
prepare the simvastatin. Plates were incubated in a culture incubator at 37^C in the presence of 20% 
O2 and 5% CO2 . Media, along with dmg or vehicle, was replaced every 48 hours for a total of 14 
days. At this point, vein rings were washed in phosphate buffered saline (PBS) then transferred to 
10% formal saline for fixing.
In situations where there was insufficient length of vein to obtain 18 rings, fewer were used.
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2.3.1 Preparation of and Maintaining Vein Rings in Organ Culture
2.3.2 Fixing and Processing of Vein Rings
Rings were placed in a solution of 10% formal saline for 24 hours. These were then transferred to 
individual tissue cassettes for placement through the tissue processor for preparation for wax 
embedding. Tissue was passed through a cycle of: 70% ethanol; 90% ethanol; Histo-clear /ethanol 
50:50 mix; Histo-clear x2; and wax x2. Following this, tissue was embedded in wax blocks in the 
correct orientation for cutting in the microtome (Leica). Sections were cut at 4pm and floated on a 
paraffin section mounting bath (Electrothermal) before being mounted on glass slides. Slides were 
treated in the oven at 60”C for 35 minutes then allowed to cool before proceeding to staining.
2.3.3 Staining of Vein Rings
Slides were stained with Haematoxylin and Eosin using an autostainer (Varistain 24-4, Thermo 
Shandon). The cycle of staining was as follows: Histo-clear 1 min x3; absolute ethanol 1 min x2; 
distilled water 1 min; Haematoxylin 6 min; distilled water 1 min; acid alcohol (0.5%) 1 min; 
distilled water Imin; Scott’s tap water substitute 2 min; distilled water 1 min; Eosin 3% 5 min; 
absolute ethanol 1 min x3; Histo-clear 1 min x4. Following staining, tissue was sealed onto the 
microscope slide by placement of a cover slip using DPX as a mounting solution.
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2.3.4 Analysis of Vein Rings
Vein sections were photographed using a Cool SNAP-Pro Color digital camera which was attached 
to an inverted light microscope. Images were taken with the vein ring under 2x magnification. At 
this magnification, the whole of the vein ring section was included in the image. These images were 
then analysed using Image-Pro Express V 4.0. This package has a facility to calculate absolute areas 
of a 2-dimensional image by tracing around the area concerned. For each image, calibration was 
performed by photographing a micrometer at the same magnification (x2) and using the calibration 
facility of the package which calibrated the programme by counting the number of pixels which 
corresponded with one micrometer. Measurements taken were: area of lumen; area to outer edge of 
tunica intima; area to outer edge of tunica media; and area to outer edge of tunica adventitia. In 
order to calculate the area of intima, the area of the lumen was subtracted from the area the outer 
edge of tunica intima. In order to calculate the area of media, the area to the outer edge of tunica 
intima was subtracted from the area to the outer edge of tunica media. For each vein ring, 3 
measures were made and the mean of this used in the analysis. The area of intima and area of media 
were expressed as a percentage of the total area to the outer edge of the tunica media. These 
different areas are shown diagrammatically in Figure 2. The amount of tunica adventitia varied 
greatly between veins since it was dependent on the amount of dissection that had been performed.
Intima
Media Lumen
Adventitia
Figure 2: Areas measured on vein rings for analysis o f intimai growth.
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2.3.5 Statistical Analysis
The impaired t test was used to analyse comparisons between the ischaemic and non-ischaemic 
veins. A p value of <0.05 was considered significant. To analyse differences within each group (i.e. 
ischaemic veins with ischaemic veins and non-ischaemic veins with non-ischaemic veins), one way 
ANOVA using randomised blocks was used. A p value of < 0.05 was considered significant. All of 
the above analyses were performed using Graph Pad Prism version 4.03 for Windows.
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2.4 Cell Culture
2.4.1 Explanting Vascular Smooth Muscle Cells
2.4.2 Maintenance of Vascular Smooth Muscle Cells in Cell Culture
Vascular smooth muscle cells were maintained in a culture incubator at 37”C in the presence of 20% 
O2 and 5% CO2  in culture medium (50:50 mix of Waymouth’s Medium and F12 Ham with 1% 
Penicillin/Streptomycin solution) containing 15% Foetal Calf Serum (FCS). Culture medium and 
FCS was replenished every 48 hours. When cells reached confluency in the well of the 6 well plate, 
they were detached using Accutase ™ (Sigma Aldrich) and transferred to culture flasks. Cells were 
grown on in the same fashion and used in cell culture experiments between Passages 3 and 5.
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It was noted that vascular smooth muscle cells (VSMC) spontaneously explanted from the vein rings 
in organ culture during the 14 day culture period. This event was expected as it had been observed in 
similar projects in the laboratory using pig coronary artery rings. When vascular smooth muscle cell 
explantation occurred, the cells were maintained after vein ring removal at day 14. These cells were 
grown to confluency then transferred to culture flasks (Nunc) for further culture. No VSMC were 
seen to explant from vein rings in the simvastatin treated group.
44
2.4.3 Cell Detachment and Flask Transfer Technique
In order to detach vascular smooth muscle cells from the culture flasks, culture medium was Iaspirated from the flask, Accutase ™ (2~5ml depending on flask size) was added to the flask which 
was then returned to the cell incubator for 10-20 minutes. Cell detachment was confirmed visually 
before neutralising the Accutase ™ using culture medium (50:50 mix of Waymouth’s Medium and 
FI2 Ham with 1% Penicillin/Streptomycin solution). The resulting cell suspension was transferred 
to a centrifuge tube and spun at 10000 rpm for 5mins. Supernatant was aspirated off before re- 
suspending the cell pellet in culture medium. This cell suspension was then either transferred in 
whole to a new flask or split between 2 or more flasks or plates for use in cell culture experiments.
2.5. Proliferation Assay
2.5.1 Preparation of Vascular Smooth Muscle Cells
Vascular smooth muscle cells were seeded onto the wells of a 24 well culture plate in the presence 
of culture medium with 15% FCS. Once cells had reached 60-70% confluency on visual inspection, 
the culture media was removed and replaced with culture media containing 0.1% FCS (quiescing 
media). Each experiment was performed in triplicate.
2.5.2 Stimulation of Vascular Smooth Muscle Cells
After a 24 hour period of incubation with quiescing medium, VSMC were stimulated by the addition 
of 15% FCS (150pl per ml of media). Some wells were left unstimulated to provide background 
counts. At the same time point, simvastatin was added to the wells in varying concentrations as well 
as mevalonate.
2.5.3 Addition of Radiolabelled Thymidine
A solution of labelled Thymidine (Amersham Biosciences) was prepared by addition of 25 pi of 
stock to 975pi of culture medium. This contained a total activity of 925kBq. lOpl of this solution 
was added to each well of the 24 well plate at 18 hours after addition of FCS. This timing was to 
correspond with the S phase of DNA replication in the cell cycle (Figure 3).
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THYMIDINE
Cell Cycle
G1 G2
Mitosis
GO- rest
Figure 3: The cell cycle. Thymidine is added to the assay at 18 hours to coincide with DNA 
replication in the S phase.
2.5.4 Assay Termination
At 24 hours following stimulation with FCS, the assay was terminated. Firstly, plates were 
visualised to confirm VSMC remained attached to the wells. Following this, media was aspirated 
from each well and cells were washed in phosphate buffered saline at 4°C. Cell membranes were 
then permeablised using 10% trichloroacetic acid (TCA) solution washes. Up to six 15 minute 
washes were required before adequate permeabilisation was visualised at high magnification. Once 
permeabilisation had been confirmed visually, remaining TCA was aspirated off before addition of 
250pl of Lauryl sulphate / Sodium Hydroxide to lyse cells. This was left overnight at 4°C.
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2.5.5 Scintillation Counting
Beta vials were loaded with 2ml of Liquid scintillation counting fluid, Emulsifier-Safe 
(Canberra-Packard) before addition of the fluid from the wells of the 24 well plate. These were 
sealed and numbered before being placed in counting racks. Disintegrations per Minute (DPM) for 
each sample were counted using a Wallac 1409 DSA Liquid Scintillation counter.
2.5.6 Statistical Analysis
Data, in the form of DPM, were normalised to controls and expressed as a percentage inhibition of 
growth. These data were compared within groups with one way ANOVA using randomised blocks. 
Also, growth inhibition curves were constructed and the 50% inhibitory concentration (IC50) was 
calculated for each experiment using the Hill equation. These were compared using the unpaired t- 
test. A p value of <0.05 was considered significant. All of the above analyses were performed using 
Graph Pad Prism version 4.03 for Windows.
47
2.6. Migration Assay
2.6.1 Preparation of Transwell ™ Inserts
The upper surfaces of Transwell Inserts with a pore size of 6pm were coated with a layer of 1% 
Collagen solution. This was allowed to dry overnight at 37°C. The inserts were maintained at this 
temperature in a 24 well plate until use.
2.6.2 Preparation and Seeding of Vascular Smooth Muscle Cells
Vascular smooth muscle cells were grown in a T75 culture flask. Once confluency was reached, 
cells were quiesced for 24 hours in medium containing 0.1% FCS (quiescing medium). Following 
this, cells were lifted from the plate using Accutase ™. The cell pellet was resuspended in 1ml of 
quiescing medium and cell density was counted using a slide haemocytometer and light microscopy 
at X100 magnification. The initial cell suspension was then diluted to a density of 5x10  ^cells per ml 
and 100 pi of this diluted cell suspension was seeded onto the upper surface of the Transwell ™ 
filter (a final cell density of 5x10  ^ cells per filter). The lower chamber was charged with plain 
quiescing media with or without PDGF (20ng/ml) and / or simvastatin 5pM. Plates and filters were 
returned to the cell culture incubator for 4 hours. Each experiment was performed in duplicate.
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2.6.3 Termination of Migration Assay and Staining of Filters
At the end of the 4 hour stimulation period. Transwell ™ inserts were placed in phosphate buffered 
saline and the remaining non-migrated cells were rubbed from the upper surface of the filter by a 
cotton bud. Following this, inserts were placed though the sequence of 3 Diff-Quik ™ solutions for 
3 minutes each to fix then stain the cells that had migrated onto the lower surface of the filter. 
Inserts were rinsed in distilled water before being allowed to dry overnight.
2.6.4 Cell Counting
Dried filters were cut away from the plastic housing of the insert and mounted on glass microscope 
slides using DPX. Cells were counted at high power (x400) for six different fields and the mean of 
this used. Counting was performed blind and verified by a second counter.
2.6.5 Statistical Analysis
The unpaired t test was used to compare the migration between VSMC from ischaemic and non- 
ischaemic veins. A p value of <0.05 was considered significant. To analyse differences within each 
group (i.e. ischaemic veins with ischaemic veins and non-ischaemic veins with non-ischaemic 
veins), one way ANOVA with randomised blocks was used. A p value of < 0.05 was considered 
significant. All of the above analyses were performed using Graph Pad Prism version 4.03 for 
Windows.
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2.7.2 Identifying Patients to be Included in the Database
Patients to be included in this database were identified by use of the Surveillance Programme 
records held at Glasgow Royal Infirmary Vascular Laboratory. Since 1991, all patients who have 
undergone infrainguinal bypass grafting have been entered prospectively into the graft; surveillance 
programme at the hospital. The programme involves ultrasound scanning at 1 month, 3 months, 6 
months and twelve months postoperatively. All scans were performed by one of two trained vascular 
technologists. Further scans are performed if there are concerns about the graft such as poor flow or
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2.7. Audit of Infrainguinal Grafts 1993-2003
2.7.1 Database Design
In order to collect information regarding patients at Glasgow Royal Infirmary who had undergone 
inft-ainguinal bypass grafting between 1993 and 2003, a database was created using Microsoft 
Access 2000. Data collected included patient details such as: date of birth, gender, pre-operative 
medications; smoking status and past medical history. For the operation: date of operation; which 
leg was operated on; Ankle-Brachial pulse index (ABPI) pre-operatively; graft inflow; graft 
outflow; and type of vein graft (in situ or reversed) used were recorded. Information on subsequent 
surveillance scans included: proximal anastomosis; flow through graft; and distal anastomosis. 
These were recorded as satisfactory, unsatisfactory or unknown. Any areas of concern (stenosis, 
fistula, aneurysm) were noted. Any secondary operations performed on the graft were recorded. 
Outcome measures recorded were: graft patency; major amputation; smoking status; medication 
status and death.
areas of narrowing. Only patients who underwent infrainguinal bypass grafting using the long 
saphenous vein were included. Furthermore, patients undergoing grafting for aneurysmal disease or 
trauma were excluded from the database. Patients who died within 30 days of surgery were also 
excluded.
2.7,3 Data Collection
Surveillance Programme records were reviewed to identify which patients had undergone graft 
surveillance between 1993 and 2003, Once these patients had been identified, their case notes were 
requested through the hospital records system. These were then used to collate further patient data as 
well as outcome data. As regards drug history, drugs were deemed positive if recorded as being used 
pre-operatively or during hospital stay. Post-operative drug use was recorded based on clinic letter 
or further hospital admissions. Smoking history was deemed positive if the pre-operative clerking 
sheet or post-operative notes indicated so. Graft patency was judged on clinical findings either at 
outpatient clinic visit or surveillance scan. Amputation was recorded only if a major amputation had 
been required but not for digital or forefoot amputation as this is not a reliable measure of graft 
function. Date of death and cause was recorded where known. Some case notes had been destroyed 
or were incomplete. In the case of destroyed notes, the patient was excluded from further analysis. 
For incomplete notes, data that could be obtained was recorded.
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2.7.4 Statistical Analysis
Descriptive statistics were used to describe the general characteristics of the group studied, quoting 
means and percentages where appropriate and quoting medians and ranges for non-parametric data.
The outcomes of graft occlusion and major amputation were analysed using a univariate model with 
regard to the operative characteristics of the graft (i.e. proximal anastomosis site, distal anastomosis 
site and orientation of long saphenous vein), patient characteristics (diabetes, gender, smoking 
status) and medication use (statin, antiplatelet and warfarin) using Fishers exact test quoting relative 
risks and 95% confidence intervals.
Kaplan-Meier survival curves were constructed to display the time to graft occlusion with respect to 
patient factors and medications. The Logrank test was used to compare curves. The same method 
was used to create Kaplan-Meier survival curves for the time to major amputation, again with 
respect to patient factors and medications. Deaths and patients lost to follow up were treated as 
censored events at the time of the event. All of the above analyses were performed using Graph Pad 
Prism version 4.03 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com.
To investigate graft occlusion fiirther, a multivariate analysis was performed using logistic 
regression with forward conditional analysis. Variables were included in the model if p<0.05 and 
excluded if p>0.10. This analysis was performed using SPSS for Windows vl3.0.
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2,8. Drugs, Reagents and Consumables Used
2.8.1 List of Drugs and Reagents Used by Supplier
Amersham Biosciences, 
Buckinghamshire, UK.
[methyi-'‘H]Thymidine
McQuilkin & Co., East Kilbride, UK. Diff-Quik ®
Canberra Packard Ltd., Pangbourne, UK. Emulsifier-Safe
Cambrex Bioscience Wokingham Ltd., 
Berkshire, UK.
Penicillin / Streptomycin
Fisher Scientific, Loughborough, UK. Histo-clear
Inverclyde Biologicals, Bellshill, UK. Phosphate buffered saline
Invitrogen Ltd.,Paisley, UK. FI2 (Ham) + L -  Glutamine 
Waymouth Medium 752/1 + L -  
Glutamine
Merk Biosciences Ltd, Nottingham, UK. Simvastatin
Sigma -  Aldrich Co Ltd., 
Poole, UK.
Accutase
Collagen Type I (from rat tail) 
Ethanol absolute 
Foetal Calf Serum 
Magnesium Sulphate 
Mevalonic Acid
Platelet Derived Growth Factor AB 
Sodium Bicarbonate 
Sodium Dodecyl Sulphate 
Trichloroacetic Acid
Surgipath Europe Ltd., 
Peterborough, UK.
Haematoxylin Gill III
VWR International, 
Poole, UK.
Acetic acid
DPX mountant for microscopy 
Eosin yellowish 
Hydrochloric acid 
Sodium hydroxide
Table 4: List o f drugs and chemicals used by supplier.
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2.8.2 Formulae of Solutions Used
Lauryl Sulphate/ Sodium Hydroxide
0.1 g Sodium Dodecyl Sulphate 
0.6g Sodium Hydroxide 
50ml distilled H2 O
Scott’s Tap Water Substitute
20g Sodium Bicarbonate 
3.5g Magnesium Sulphate 
1000ml distilled H2O
0.5 % Acid Alcohol
70ml Ethanol absolute 
30ml distilled H2 O
0.5ml concentrated Hydrochloric Acid
2.8.3 Plasticware Used
VWR International, Coming Costar 6 well plate
Poole, UK. Coming Costar 24 well plate
Costar Cell Culture Inserts, Trans well ™
Polycarbonate Membranes, 6 pm pore
Nunc Cell Culture Flasks, Easy Flask ™
Table 5: List o f plasticware used by supplier.
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Chapter 3
RESULTS
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3.1 Patients Involved in the Experimental Study
3.1.1 Introduction
The principal aim of this study was to determine whether profound tissue ischaemia in a lower limb 
affected the way in which the long saphenous vein would respond to organ culture. Long saphenous 
vein taken from patients undergoing amputation due to severe ischaemia was to constitute one of the 
groups. It was essential that non-ischaemic veins were taken from a comparable patient group. 
Obtaining long saphenous vein from patients undergoing varicose vein surgery would certainly have 
provided large amounts of non-ischaemic tissue but the patient characteristics would have been very 
much different when compared to patients undergoing amputation. It was decided that the most 
comparable group of patients would be those undergoing aorto-coronary bypass grafting for 
ischaemic heart disease.
3.1.2 Summary of Patients Involved in the Study
A total of twenty patients were consented and entered into the study. A total of 11 ischaemic veins 
(IV) and 9 non-ischaemic veins (NIV) were obtained. A portion of long saphenous vein was 
obtained from each patient. Table 6 lists the order in which these vein specimens were obtained as 
well as the age and sex of each patient.
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PATIENT
NUMBER
Age Sex ISCHAEMIC OR NON- 
ISCHAEMIC LIMB
2 72 M Ischaemic
3 86 F Ischaemic
5 45 F Ischaemic
6 62 M Ischaemic
8 60 M Ischaemic
9 77 M Ischaemic
10 75 F Ischaemic
11 65 F Non-ischaemic
12 68 F Non-ischaemic
13 76 M Non-ischaemic
14 76 M Non-ischaemic
15 74 M Non-ischaemic
16 78 M Non-ischaemic
18 81 F Ischaemic
19 65 M Ischaemic
20 47 M Non-ischaemic
21 68 M Ischaemic
22 66 M Non-ischaemic
23 55 M Ischaemic
24 50 M Non-ischaemic
Table 6: Summary o f characteristics ofpatients involved in the study in order o f obtaining vein 
portion.
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3.1.3 Comparison of Patients Involved in the Study
It was expected that the two groups of patients would be of comparable age and sex distribution. 
Other factors such as diabetes, total number of medications in use and current smoking history were 
thought to possibly be less comparable. Table 7 shows a comparison of these factors.
Characteristic Ischaemic (n=l 1) Non-ischaemic (n=9)
M:F 7:4 7:2
Median Age (range) 68 (45-86) 68 (47-78)
Smokers 4 2
Diabetic 6 2
Median number of 
medications (range)
5 (2-12) 5 (2-10)
Statin prescription 4» 8*
Table 7. Comparison o f characteristics o f the two patient groups involved in the study. Statistics: 
Mann-Whitney test to compare age and total number o f medications, p=1.00 and p-0.90, 
respectively; Fishers exact test used to compare sex, p=0.64; prevalence o f smoking, p=0.64; and 
prevalence o f diabetes, p=0.20. * Fishers exact test to compare statin prescription, p=0.03.
It can be seen that the two groups are well matched with regard to age, smoking history, diabetes 
and total number of medications in use. The only significant difference between the two groups 
other than the presence of profound tissue ischaemia is statin prescription. Patients undergoing 
coronary artery bypass grafting are significantly more likely to be prescribed a statin than those 
patients undergoing lower limb amputation for ischaemia.
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3.2 Organ Culture
3.2.1 Introduction
Vein rings maintained in organ culture develop thickening of the intimai layer which is similar, in 
many ways, to the pathological changes seen in vein graft stenoses. In both cases, the intimai layers 
contain an abundance of VSMCs of a secretory phenotype and the composition of the extracellular 
matrix is very similar (127). Intimai thickening in the organ culture model is maximal at 14 days and 
does not change after this time (127). In addition, the majority of proliferating cells are VSMC that 
have migrated into the intima from the vessel media (128) and use of this organ culture technique as 
a model of intimai hyperplasia has been validated as a useful model of vein graft stenosis (92). 
Previous authors have demonstrated intimai thickening in vein rings maintained in organ culture 
from patients undergoing coronary artery bypass grafting and that simvastatin reduced the amount of 
intimai thickening in a dose-dependent manner, and by 75% at a concentration of 5pM (102). The 
technique of vein ring organ culture was chosen in this thesis to compare the effects of organ culture 
on vein rings from two groups of patients: those undergoing lower limb amputation; and those 
undergoing coronary artery bypass grafting (CABG). The veins from the patients undergoing lower 
limb amputation have been exposed to severely ischaemic conditions prior to use in this model 
(Ischaemic veins), whereas the veins from the CABG group have not (Non-ischaemic veins). It may 
be that the Ischaemic veins are more susceptible to the development of intimai hyperplasia in organ 
culture compared with Non-ischaemic veins due to the adverse effects of prolonged tissue ischaemia 
and that simvastatin may have an effect on this process of intimai hyperplasia in organ culture.
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3.2,2 General Observations of the Effect of Organ Culture
From published data, it was expected that organ culture for 14 days would result in intimai growth 
in the human long saphenous vein from non-ischaemic limbs. The response of veins from ischaemic 
limbs was not known. Figures 4, 5 and 6 are photographs from vein rings and have been chosen to 
give a representative view of the differences between the groups and the changes seen after organ 
culture.
In freshly fixed vein (Figure 4a) the three layers of the vein wall (Tunica Intima, Tunica Media and 
Tunica Adventitia) can be easily identified. The very thin intimai layer is shown in more detail in 
Figure 4b and contains few cells, mainly myointimal cells and endothelial cells.
Following culture for 14 days in culture medium alone, the intimai layer is much thicker and 
contains many more cells, often appearing in groups (Figure 5). These cells appear to be smooth 
muscle cells. Between these cellular areas, there are areas of increased extracellular matrix which 
has been deposited.
Figure 6 is a photograph of a vein ring following 14 days of culture in culture medium plus 
Simvastatin 5pM. It can be seen that the development of intimai hyperplasia in this specimen is less 
than that in Figure 5. There is still an increase in the thickness and cellularity of the intimai layer 
although it is not as pronounced as in the absence of simvastatin. There is also an increase in 
extracellular matrix, but again, not as pronounced as in Figure 5.
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MFigure 4a: Section o f fresh fixed vein at xlOO magnification. L=Lumen; /= Tunica Intima; M= 
Tunica Media; Tunica Adventitia. Area enclosed in box is shown at x400 magnification in 
Figure 4b below. Staining is with Haematoxylin and Eosin.
EC
jr
VSMC\
Figure 4b: Detail from Figure 4a at x400 magnification. IEL=Internal elastic lamina,
EC=endothelial cell, VSMC=vascular smooth muscle cell.
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Figure 5a: Section o f vein after culture for 14 days in culture medium alone at xlOO magnification. 
L=Lumen; /= Tunica Intima; M= Tunica Media. Area enclosed in box is shown at x200 
magnification in Figure 5b below. Staining is with Haematoxylin and Eosin.
VSMC
Figure 5b: Detail from Figure 5a at x200 magnification showing intimai hyperplasia with numerous
vascular smooth muscle cells (VSMC) within extracellular matrix.
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MFigure 6a: Section o f vein after culture for 14 days in culture medium with 5pM simvastatin at xlOO 
magnification. L=Lumen; 1= Tunica Intima; M= Tunica Media. Area enclosed in box is shown at 
x400 magnification in Figure 6b below. Staining is with Haematoxylin and Eosin.
E
VSMC
» •
Figure 6b: Detail from Figure 3a at x400 magnification. lEL=lnternal elastic lamina,
E=endothelial cell, VSMC=vascular smooth muscle cell.
63
3.2.3 Summary of Organ Culture Data from Ischaemic Veins
Organ culture was not completed in veins from patients number 2 and 5. In both cases, the vein 
rings showed evidence of bacterial infection within the first 72 hours of culture, suggesting that 
contamination occurred at the time of dissection. Of the remaining 9 veins, organ culture was 
continued for the full 14 days as described in Section 2.3. Therefore, «=9 for ischaemic vein rings in 
the following results.
3.2.4 Observed Effects of Organ Culture on Ischaemic Veins
Vein rings from ischaemic limbs which had been maintained in organ culture for 14 days showed 
growth of the intimai layer when compared with the fresh fixed vein rings. The presence of 
simvastatin at 5pM for the duration of organ culture appeared to abolish this process. One-way 
ANOVA using randomised blocks was used to compare intimai areas between the 3 groups: fresh 
fixed, culture alone and culture with simvastatin. There was a significant difference in the 
percentage area of intima between fresh fixed and culture alone groups and between culture alone 
and culture with simvastatin. There was no difference between the fresh fixed and culture with 
simvastatin groups. Figure 7 is a graphic representation of the differences in intimai areas.
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3.2.5 Summary of Organ Culture Data from Non-Ischaemic Veins
Organ culture was completed all veins except vein number 16 from the non-ischaemic limbs. 
Therefore, n=% for non-ischaemic vein rings in the following results.
3.2.6 Observed Effects of Organ Culture on Non-ischaemic Veins
Vein rings from non-ischaemic limbs, which had been maintained in organ culture for 14 days, 
showed growth of the intimai layer when compared with the fresh fixed vein rings. The presence of 
simvastatin at 5pM for the duration of organ culture suppressed this process. One-way ANOVA 
using randomised blocks was used to compare intimai areas between the 3 groups: fresh fixed, 
culture alone and culture with simvastatin. As in the comparisons for ischaemic veins, there was a 
significant difference between fresh fixed and culture alone groups and culture alone and culture 
with simvastatin. There was also a significant difference between fresh fixed and culture with 
simvastatin in the non-ischaemic veins. This suggests that the vein rings were less responsive to the 
presence of simvastatin in the organ culture than the veins from ischaemic limbs. Figure 8  is a 
graphic representation of the differences in intimai areas.
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Figure 7; Comparison o f percentage areas as intima between ischaemic veins. **"*p<0.001, ** 
p<0.01 (n=9). One-way ANOVA.
4* ^  ^***
Fresh R)ed CiitureAbne CultLfe&Sim^etalin
Figure 8: Comparison o f percentage areas as intima between non-ischaemic veins. *** p<0.001, 
*p<0.05 (n^S). One-way ANOVA.
6 6
3.2.7 Comparison of Ischaemic and Non-ischaemic Vein Organ Culture
Ischaemic vein rings developed a greater amount of intima compared with Non-ischaemic vein rings 
(45.8% from 22.3% vs 35.8% from 16.2%) in culture alone. In the fresh fixed and culture with 
simvastatin vein rings, there was no difference between the amount of intima between the two 
groups. This is shown in Figure 9.
B  40
A 30
Fresh Fixed Culture Alone Culture & 
Simvastatin
Figure 9: Comparison o f percentage areas as intima between Ischaemic Veins (n=9) (IV) and Non- 
ischaemic Veins (n=8) (NIV). "^p=0.04. Unpairedt-test.
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3.2.8 Changes in the Absolute Area of Tunica Intima and Tunica Media
The absolute area of tunica intima and tunica media was calculated for each vein ring. Table 8  
shows the mean absolute intimai and medial areas for Non-ischaemic vein rings and Table 9 shows 
this for Ischaemic vein rings.
Mean intimai area, (im  ^
(SEM)
Mean medial area, pm^ 
(SEM)
Fresh Fixed 0.495 (0.095) 2.649 (0.380)
Culture with Simvastatin 0.674 (0.142) 2.538 (0.373)
Culture Alone 0.874(0.157) 1.796 (0.334)
Table 8: Intimai & Medial areas for Non Ischaemic vein rings. n=^ 8
Mean intimai area, jam^  
(SEM)
Mean medial area, pm^ 
(SEM)
Fresh Fixed 0.523 (0.197) 1.558(0.435)
Culture with Simvastatin 0.674 (0.202) 1.530 (0,366)
Culture Alone 1.045 (0.332) 1.056(0.331)
Table 9: Intimai & Medial areas for Ischaemic vein rings. n=^ 9
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The mean absolute intimai area increased in both groups from the fresh fixed group to the culture 
with simvastatin group and also from the fresh fixed group to the culture alone group. There was a 
corresponding overall decrease in the area of tunica media. On analysing this data using one-way 
ANOVA with repeated measures, the difference between the fresh fixed intimai area and intimai 
area after culture alone was significant in both groups (Table 10). This confirms that there is a 
change in the intima area whether expressed as percentage of the total vessel wall or as an absolute 
value. However, the difference in absolute intimai area between fresh fixed rings and rings cultured 
with simvastatin was not statistically significant. Partially, this is a reflection of the variability of 
intimai area from vein to vein which can also be seen in the high standard errors.
The mean absolute medial areas show a decrease from the fresh fixed group to the culture with 
simvastatin group and also from the fresh fixed group to the culture alone group. This change in area 
of media mirrors the changes seen in the tunica intima of the vein rings and is likely to be due to 
migration of the smooth muscle cells from the media into the intima. However, the change in medial 
area is statistically significant only for the non-ischaemic vein rings between the fresh fixed and 
culture alone groups and between the culture alone and culture with simvastatin groups (Table 11). 
This may reflect the variability of medial area from vein to vein which can also be seen in the high 
standard errors.
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Comparison of Intima Areas P
Non-ischaemic Veins Fresh fixed vs Culture Alone <0.05
Fresh fixed vs Culture with 
Simvastatin
>0.05
Culture Alone vs Culture with 
Simvastatin
>0.05
Ischaemic Veins Fresh fixed vs Culture Alone <0.05
Fresh fixed vs Culture with 
Simvastatin
>0.05
Culture Alone vs Culture with 
Simvastatin
>0.05
Table 10: Statistical comparison o f absolute tunica intima areas for Non-ischaemic and Ischaemic 
Veins. One-way ANOVA with repeated measures.
Comparison of Media Areas PNon-ischaemic Veins Fresh fixed vs Culture Alone <0 . 0 1
Fresh fixed vs Culture with 
Simvastatin
>0.05
Culture Alone vs Culture with 
Simvastatin
<0 . 0 1
Ischaemic Veins Fresh fixed vs Culture Alone >0.05
Fresh fixed vs Culture with 
Simvastatin
>0.05
Culture Alone vs Culture with 
Simvastatin
>0.05
Table 11: Statistical comparison o f absolute tunica media areas for Non-ischaemic and Ischaemic 
Veins. One-way ANOVA with repeated measures.
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3.2.9 Discussion of Organ Culture Findings
In organ culture for 14 days, vein rings from Ischaemic and Non-ischaemic limbs develop 
significant growth of the intimai layer. This response was expected in the veins from Non-ischaemic 
limbs as it had been demonstrated previously (92; 102). However, direct comparison of this data with 
that from these authors is not possible as both used intimai thickness rather than intimai area. The 
problem with using intimai thickness is that it cannot distinguish between a vessel which has 
remodelled in culture and a vessel which has developed intimai growth as both will appear to have a 
thicker tunica intima. Additionally, Porter et al did not quote baseline intimai thickness (that is, 
before organ culture (fresh fixed). Instead, the authors use veins cultured in culture medium with 
growth factors alone as their control measure of intimai growth compared with organ culture in the 
presence of variable concentrations of drug. Huang et al also use intimai thickness but compare this 
with baseline pre-culture thickness. The data presented in this thesis is, therefore, novel in two ways. 
Firstly, it gives a more accurate reflection of actual changes in the vessel wall composition by 
measuring absolute intimai and medial areas in order to calculate percentage contribution to the 
vessel wall. Additionally, this is the first study showing data on veins from Ischaemic limbs. It was 
observed that the amount of intimai growth was significantly greater in the Ischaemic vein rings 
when compared with the Non-ischaemic vein rings. This finding suggests that the vein response has 
been pre-programmed by the conditions prior to organ culture, that is, tissue ischaemia.
The addition of simvastatin at a concentration of 5pM to the organ culture reduced the intimai 
growth in both Ischaemic and Non-ischaemic vein rings. This effect was expected in the Non- 
ischaemic vein rings but had not previously been demonstrated in vein rings from Ischaemic limbs. 
The effect of simvastatin may be related to both its antiproliferative and anti-migratory effects on 
VSMC. From my data, the Ischaemic vein rings appear to show a greater response to the presence of
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simvastatin than the Non-ischaemic vein rings. A possible explanation is that there is enhanced 
VSMC proliferation and migration in the Ischaemic Vein rings, thereby making the cells more 
susceptible to the effect of the statin. This effect may suggest a therapeutic target for simvastatin in 
patients undergoing both infrainguinal bypass grafting for lower limb ischaemia as well as patients 
undergoing coronary artery bypass grafting to prevent graft stenosis. It is important, however to also 
point out that the numbers achieved in these organ culture experiments were small and the apparent 
differences between the two groups may be due to a Type I statistical error.
The concentration of simvastatin chosen for these organ culture experiments, 5pM, was based on 
my observations in experiments on cell proliferation (see Section 3.3). This concentration also 
compares with work by previous authors (102; 109). How this concentration in organ culture 
compares with expected tissue levels of simvastatin during oral administration is not clear. Oral 
doses of simvastatin vary from lOmg to 80mg per day. Studies on the pharmacokinetics of 
simvastatin show that it is readily absorbed orally but is extensively metabolised by first pass 
hepatic metabolism. As such, plasma concentrations of simvastatin are in the region of 5-20nM 
(129; 130). Furthermore, 95% of circulating simvastatin is protein-bound and more than three 
quarters of this is in the inactive form (129;131). Based on these facts, it can be seen that the 
concentration used in my organ culture experiments is much greater than levels that could be 
expected in patients treated with normal doses of simvastatin. However, the concentration chosen 
for these experiments is in line with the concentrations used in previous studies demonstrating 
antiproliferative effects of statins (102; 132). How this fits with the observations of Henke et al and 
Abbruzzese et al who both associated improved graft patency with statin therapy, is not clear. The 
patients in both of these studies received oral statins in normal doses. This could not have delivered 
sufficiently high enough local concentrations to the vein grafts in order to exert a direct 
antiproliferative effect. It is possible, however, that the improved graft patency seen by these authors
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was not due to a direct inhibition of VSMC proliferation. Instead, the effects may have been 
mediated by other factors, such as increased bioavailability of nitric oxide (NO) which has been 
shown to repress cell proliferation by inhibiting p21 upregulation. Certainly, normal oral doses of 
statins have been shown to improve endothelial dependent vasodilation measured by forearm blood 
flow. Since simvastatin has been shown in the present study to have antiproliferative effects on 
VSMC explanted from ischaemic long saphenous veins (see section 3.3), it would not be 
unreasonable to attempt to use this effect in order to prevent graft stenosis. Possible ways to do this 
include use of local high dose delivery systems. This could be in the form of a drug eluting suture 
which would release the drug over a prolonged period of time. Another possibility would be to bathe 
the vein in a statin solution just prior to inserting it as a graft.
The only differences between the two groups of veins obtained in this study were presence or 
absence of prolonged tissue ischaemia before culture and statin prescription (see Section 3.1.3). The 
effect of prolonged tissue ischaemia has not previously been investigated. It is likely, however, that 
the tissue, and therefore cellular ischaemia activates stress pathways in the vein cells. Possible 
pathways include the mitogen activated protein kinase (MAP Kinase) p38 pathway. This pathway 
stimulates cell proliferation responses and has been shown to cause vascular hypertrophy in patients 
with pulmonary vascular hypoxia leading to pulmonary hypertension (133). Another pathway that 
may be involved is the MAP Kinase p42/p44 pathway which leads to cellular proliferation and 
migration (134). Further work investigating the role of these MAP Kinase pathways would clarify 
their role. Another question is what would be the response of vein rings cultured under hypoxic 
conditions.
It is possible, that the prior medication of the patient with statin influenced the outcome of the 
experiments. This is unlikely for a few reasons. Firstly, based on known pharmacokinetics of statins,
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the plasma concentrations are very low and most of the drug is protein bound. Additionally, all vein 
rings were washed in blank media before culture which would remove any surplus drug and the 
frequent replenishment of culture medium would likely have facilitated the removal of any residual 
statin. These arguments, however, do not account for any cellular-level changes which may have 
occurred as a result of statin therapy before vein harvest.
Organ culture was completed in nine out of eleven ischaemic veins. Of these veins, three came from 
patients with prior treatment with a statin (vein numbers 8 , 9 and 19). One of the veins in which 
organ culture was not completed came from a patient taking a statin. Unfortunately, these numbers 
are too low to perform any statistical subgroup analysis, but on reviewing the data on intimai areas, 
there is no apparent trend in the responses of these veins compared to veins from patients who did 
not receive a statin pre-operatively. Of course, it cannot be said with certainty that prior treatment 
with a statin could influence the experimental results. Unfortunately, however, in light of the 
overwhelming evidence that patients with atherosclerotic disease should be prescribed a statin, there 
is little feasibility of performing a study to investigate this point.
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3.3 Vascular Smooth Muscle Cell Proliferation
3.3.1 Introduction
Vascular smooth muscle cells (VSMCs) in the walls of arteries and veins are normally in a relatively 
quiescent state. Activation of VSMC leading to proliferation and migration are key steps in the 
development of intimai hyperplasia and atherosclerosis.
3.3.2 Proliferation of Cells Explanted from Ischaemic and Non-ischaemic Vein Rings
VSMCs were explanted from vein rings and used in cell proliferation studies (see Section 2.5). Each 
experiment was performed in triplicate between Passage 3 and 5. (Ischaemic Veins, n=6 ; Non- 
ischaemic Veins, n=6 ).
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3.3.3 Statistical Analysis of Proliferation Data from Cells Explanted from Ischaemic and Non- 
ischaemic Vein Rings
Simvastatin caused a concentration-dependent inhibition of VSMC proliferation as measured by 
incorporation of ^H-thymidine. This was reversed by the addition of mevalonate lOOpM. Data is 
presented (Figures 10 & 11) as absolute values, and is shown normalised to controls (Figure 12) as a 
percentage reduction in proliferation. The mean 50% inhibitory concentration (IC50) for VSMC 
explanted from Ischaemic Vein rings was 1.16pM (+/- Standard error of mean (SEM), 0.46pM). 
The mean IC50 for VSMC explanted from Non-ischaemic Vein rings was l,22pM (+/- SEM, 
0.33pM). The IC50S were calculated using the Hill equation and were not statistically significantly 
different when compared using the unpaired t test.
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Figure 10: Effect o f Simvastatin on 3H-Thymidine incorporation o f VSMCs from Ischaemic Vein 
Rings. Quiesced= unstimulated cells, Mev= Mevalonate lOOpM. One way ANOVA with randomised 
blocks, **p<0.01, ***p<0.001. n=6
ns
* * * * * *
Q_
Û
14000
12000
10000
8000
6000
4000
2000
0
Quiesced
iliü
0.1 0.3 1 3
Concentration of simvastatin (uM)
a  ■■ 
10 3 + Mev
Figure II: Effect o f Simvastatin on 3H-Thymidine incorporation o f VSMCs from Non-ischaemic 
Vein Rings. Quiesced^ unstimulated cells, Mev= Mevalonate lOOpM. One way ANOVA with 
randomised blocks, ***p<0.001. n=6
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Figure 12: Effect o f Simvastatin on VSMC proliferation from Ischaemic and Non-ischaemic Vein 
Rings. IC50 I.I6juM (+/- SEM 0.46pM) and 1.22pM  ( 4- / -  SEM 0.33pM) for Ischaemic and Non- 
ischaemic rings respectively (p=ns). Unpaired t test.
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3.3.4 Discussion of Cell Proliferation Results
Vascular smooth muscle cell proliferation is stimulated by activation of the mitogen-activated 
protein kinase (MAP Kinase) pathways. The MAP Kinase pathways are usually activated in 
response to growth factor stimulation and include the extracellular signal-regulated kinases 1 and 2  
(ERKl and ERK2) as well as the stress-activated protein kinases (SAPK or p38 MAPK). These 
pathways are activated by various signals from second messengers and result in cell proliferation or 
differentiation (135). Statins have been shown to inhibit VSMC proliferation in vitro both in cell 
culture and organ culture models (102; 136). However, the response of VSMCs to statins appears to 
be dependent on factors such as animal of origin and also tissue of origin. For example, Corsini et al 
found that cultured rat aorta VSMCs had a similar IC50 for simvastatin and fluvastatin at 2.2 and 
2.8pM, respectively. However, the authors found that proliferation of human femoral artery VSMCs 
is inhibited at lower concentrations of these two statins (137). Furthermore, another rat model 
showed that VSMCs explanted from post-angiopasty neointimal lesions are more susceptible to 
statin-induced apoptosis than VSMCs explanted from the rat thoracic aorta (138).
Given these observed differences it may also be expected that VSMCs from Ischaemic and Non- 
ischaemic veins could respond differently to simvastatin. The principal aim of my experiments was 
to delineate any such difference. My data from the organ culture of vein rings (see section 3.2.6 and 
3.2.7) has suggested a difference in the proliferative response to culture and the inhibition of this 
response to the presence of simvastatin between Ischaemic and Non-ischaemic veins. The Ischaemic 
vein rings were more susceptible to the presence of simvastatin and this could possibly have been 
due to an enhanced antiproliferative effect of simvastatin on the VSMCs. My cell culture 
experiments, however, have not demonstrated any difference in inhibition of VSMC proliferation 
between cells from Ischaemic and Non-ischaemic veins. This may suggest that there is an additional
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effect of the surrounding vein wall matrix on the VSMC proliferation response which is lost once 
the VSMCs are freed from this surrounding environment.
With regard to the possible mechanism of VSMC proliferation inhibition, addition of mevalonic 
acid to the assays completely reversed the effect of simvastatin. Tliis is evidence that the mechanism 
of inhibition is through reduction of intracellular mevalonic acid, a precursor of famesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These are lipid attachments 
necessary for the membrane localisation of G proteins including, ras, rho and rac. Although these 
experiments were not designed to establish the cellular meehanism of inhibition of VSMC 
proliferation by simvastatin, it is likely that its action is by this mechanism.
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3.4 Vascular Smooth Muscle Cell Migration
3.4.1 Introduction
Migration of vascular smooth muscle cells (VSMCs) from the tunica media into the tunica intima is 
an important step in the development of intimai hyperplasia. Given that veins from ischaemic limbs 
showed a greater degree of intimai hyperplasia in organ culture compared with veins from non- 
ischaemic limbs, it was hypothesised that this may be due, in part, to a greater degree of VSMC 
migration in veins from the ischaemic limbs.
3.4.2 Migration of Cells Explanted from Ischaemic Vein Rings
VSMCs were explanted from vein rings in organ culture and used in cell migration studies (see 
Section 2.6). Each experiment was performed in duplicate. For the data presented here, n=5.
3.4.3 Statistical Analysis of Migration Data from Cells Explanted from Ischaemic Vein Rings
In the absence of simvastatin, PDGF 20ng/ml caused extensive migration of VSMC compared with 
quiesced cells. Addition of mevalonate to the PDGF did not significantly alter the amount of VSMC 
migration. In the presence of simvastatin, PDGF still caused significant VSMC migration compared 
with quiesced cells. Addition of mevalonate did not alter the degree of VSMC migration. VSMC 
migration in the presence of PDGF appeared to be reduced but not significantly by the addition of 
simvastatin. These results are displayed in Figure 13.
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Figure 13: VSMC migration from cells explanted from Ischaemic Veins. PDGF= Platelet derived 
growth factor, MEV- mevalonate, S= Simvastatin, Quiesc .= Quiesced,. ***p<0.001. One way 
ANOVA with randomised blocks. n^5
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3.4.4 Migration of Cells Explanted from Non-ischaemic Vein Rings
VSMCs were explanted from vein rings in organ culture and used in cell migration studies (see 
Section 2,6) at passage 3 or 4. Each experiment was performed in duplicate. For the data presented 
here, n=8 .
3.4.5 Statistical Analysis of Migration Data from Cells Explanted from Non-ischaemic Vein 
Rings
In the absence of simvastatin, PDGF 20ng/ml caused significant migration of VSMC compared with 
quiesced cells. Addition of mevalonate to the PDGF did not significantly alter the amount of VSMC 
migration. In the presence of simvastatin, PDGF still caused significant VSMC migration compared 
with quiesced cells. Addition of mevalonate did not alter the degree of VSMC migration. Again, 
VSMC migration in the presence of PDGF appeared to be reduced but not significantly by the 
addition of simvastatin (Figure 14).
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Figure 14: VSMC migration from cells explanted from Non-ischaemic Veins. PDGF^ Platelet 
derived growth factor, MEV^ mevalonate, S= Simvastatin, Quiesc .= Quiesced. *** p<0.001. One 
way ANOVA with randomised blocks. n=8
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3.4.6 Comparison of Migration Between Ischaemic and Non-ischaemic Vein Cells
The basal level of VSMC migration in quiesced cells was not significantly different in cells from the 
Ischaemic and Non-ischaemic groups. However, PDGF stimulated migration of VSMCs fi'om the 
Ischaemic veins more strongly when compared with the response of VSMC from Non-ischaemic 
Veins. This remained true in the presence of mevalonate (Figure 15).
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Figure 15. Comparison o f VSMC migration between cells from Ischaemic and Non-ischaemic Veins. 
PDGF= Platelet derived growth factor, MEV = mevalonate. *p=0.04, **p=0.009. Unpaired t-test. 
Ischaemic veins, n=5, Non-ischaemic veins, n=8.
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3.4.7 Discussion of Cell Migration Results
From this data, VSMC expianted from Ischaemic vein rings demonstrate a greater degree of 
migration when stimulated with PDGF compared with cells explanted from Non-Ischaemic vein 
rings. No significant alteration in the migration response was elucidated by the addition of 
simvastatin at a concentration of 5|xM.
The process of cell migration involves three key stages. Firstly, an external stimulus causes 
polarisation of the cell and the extension of a cell protrusion in the direction of movement. 
Following this, the protrusion adheres to the substance on which the cell is migrating. Finally, 
contraction of the cell in the direction of migration along with release of adhesions at the rear of the 
cell, allows the cell to move forward (145). The cellular mechanisms involved in this process are 
complex. An early key step in cell polarisation is the activation of cell division cycle 42 (Cdc42). 
Inhibition of Cdc42 causes cells to lose the ability to migrate directionally in response to a 
concentration gradient. Assembly and polymerisation of actin filaments in the cell leading edge is 
controlled by the small GTP-binding proteins, Rho and Rac (139; 140).
The increased rate of migration, demonstrated by VSMCs from the Ischaemic vein rings when 
stimulated by PDGF, could be explained by changes in membrane PDGF receptor expression. 
PDGF receptor expression (a and P) is known to be altered in response to autocrine factors such as 
transforming growth factor -  p (TGF-P) (141). Another possibility is a change in the intracellular 
signalling responses such as upregulation of the MAP Kinase p38 system. This system lies 
downstream of the GTP-binding proteins Cdc42 and Rac. It may be that profound tissue hypoxia 
leads to activation of MAP Kinase p38, with subsequently amplified responses to a migratory
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stimulus. Hypoxia has previously been shown to stimulate the MAP Kinase p38 pathway in 
pulmonary fibroblasts and cardiac myocytes (142; 143).
Mevalonate is a precursor, not only of intracellular cholesterol synthesis, but also of isoprenylation 
compounds famesyl pyrophosphate (FPP) and geranyl geranyl prophosphate (GGPP). These 
compounds are necessary for the membrane localisation of small GTP-binding proteins including 
Ras, Rac and Rho. By blocking the membrane translocalisation of these proteins, statins could be 
expected to inhibit the effects of these proteins, including VSMC migration.
In my data, there was some inhibition of migration of smooth muscle cells by simvastatin. This 
effect approached but did not reach statistical significance. It is possible that this reflects a Type II 
error as the numbers are low (n=5 for cells explanted from ischaemic vein rings and n= 8  for those 
explanted from the non-ischaemic vein rings.) in both groups. Further experiments would be needed 
to clarify this. Another possibility is that the concentration of simvastatin used was too low. 
However, previous studies have used similar concentrations of simvastatin and found an inhibition 
of cell migration (102;144). This raises the possibility that the stimulus for migration, PDGF was 
used in too high a concentration (2 0 ng/ml).
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3.5 Audit of Infrainguinal Graft Outcome 1993-2003
3.5.1 Introduction
The outcome of infrainguinal bypass grafting is most commonly measured by graft patency and 
limb salvage rates. Section 1.3 describes factors which are known to influence vein graft patency. 
This section of the thesis aims to analyse the graft patency rates and limb salvage rates for 
infrainguinal vein bypasses performed at Glasgow Royal Infirmary between 1993 and 2003. These 
outcomes are correlated with operative characteristics (graft inflow, outflow and conduit), patient 
characteristics (gender, diabetes and smoking) and medication use (statin, antiplatelets and 
warfarin).
Patients were identified to be included in the study from graft surveillance records at Glasgow Royal 
Infirmary. Since 1991, all infrainguinal bypass grafts performed at the hospital have undergone 
ultrasound surveillance for the first year after surgery. The case notes for all patients who underwent 
graft surveillance between Jan 1993 and Jan 2003 at Glasgow Royal Infirmary were reviewed. 
Previous studies have shown that one third of infrainguinal bypass grafts develop an area of 
significant stenosis in the first year after surgery (73;74). Surveillance of grafts using ultrasound can 
detect these stenoses and allow for repair before the graft occludes. This technique of surveillance 
and repair has been shown to improve the medium term patency of infrainguinal grafts but not 
eventual limb salvage rates (74).
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3.5.2 Basic Analysis of Infrainguinal Grafts 1993-2003
Between January 1993 and January 2003, 207 infrainguinal grafts in 194 patients underwent 
surveillance. Of these, the case notes had been destroyed in 46 grafts and at the end of my research 
time frame, the case notes for a further 28 grafts could not be obtained. In total, I have reviewed the 
case notes for 133 of the 207 grafts (64%). With regard to the case notes which have been destroyed 
or were not available, some information was obtained from the surveillance database, allowing the 
following results to be collated. Figure 16 shows a breakdown of the number of grafts per year and 
the proportion of case notes that were destroyed or not seen. Table 12 shows some of the basic 
characteristics of the patients who underwent bypass grafting.
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Figure 16: Number o f infrainguinal grafts per year. Total number o f grafts = 207.
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All Grafts Grafts- notes seen
Number of grafts 207 133
Number of patients 194 122
Median Age at operation 67 66
Age Range 38-91 42-86
Males: Females 123:71 83:50
Side: Left:Right:Unknown 103:97:7 68:64:1
Table 12: Basic characteristics o f the patients that underwent infrainguinal bypass grafting.
3.5.3 Concurrent Medical Conditions
Patients with peripheral vascular disease have a high incidence of concurrent medical conditions, 
mainly those associated with atherosclerosis. Of the 122 patients whose notes were reviewed, 115 
had information regarding concurrent illnesses. The median number of concurrent illnesses was 2 
(range 0-5). The commonest condition recorded was hypertension (46 patients), followed by 
diabetes (36 patients), ischaemic heart disease (30 patients), cerebrovascular disease (18 patients) 
and myocardial infarction (12 patients). Nineteen patients had also previously undergone major 
vascular surgery. These details along with the other conditions are shown in Table 13. It is 
interesting to note that very few patients were labelled with a diagnosis of hypercholesterolaemia at 
the time of bypass grafting. This is likely to be due to the fact that serum cholesterol levels were not 
routinely measured pre-operatively in these patients in the past. Furthermore, the evidence regarding 
the effect of statins in patients with “normal” cholesterol levels but a history of cardiovascular 
disease has only recently been established.
Condition Number of Patients Affected (%)
Hypertension 46 (40%)
Diabetes 36 (31%)
Ischaemic Heart Disease / Angina 30 (26%)
Previous Vascular Surgery 19 (17%)
Cerebrovascular disease 18 (16%)
Previous Myocardial Infarction 12 (10%)
Chronic Obstructive Pulmonary 
Disease (COPD) /Asthma
13(11%)
Congestive Cardiac Failure 6 (5%)
Atrial Fibrillation 5 (4%)
Hypercholesterolaemia 4 (3%)
Coronary Bypass Grafting 3 (2.6%)
Chronic Renal Failure 2 (1.7%)
Venous Ulceration / Thrombosis 3 (2.6%)
Epilepsy 2 (1.7%)
Alcoholism 2 (1.7%)
Polycythaemia 2 (1.7%)
Prostate Cancer 1 (0.8%)
Rheumatoid Arthritis 1 (0.8%)
Cognitive Impairment 1 (0.8%)
Myeloproliferative Disorder 1 (0.8%)
No concurrent illness recorded 12 (10%)
Table 13: Concurrent medical conditions o f patients undergoing infrainguinal bypass grafting.
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3.5.4 Types of Infrainguinal Grafts
Information regarding the proximal anastomosis site, distal anastomosis site and material used for 
the graft was extrapolated from a combination of the case notes and the surveillance scans. The 
proximal anastomosis site was the Common Femoral Artery (CFA) in 146 grafts, a previous Aortic 
Bifurcation Graft (ABG) in 15 grafts and from the External Iliac Artery (ElA) in 7 grafts. The site of 
distal anastomosis was at the above knee Popliteal Artery in 59 grafts, the below knee Popliteal 
Artery in 47 grafts, the tibial vessels in 55 grafts and unknown in 46 grafts. The conduit for all these 
grafts was the long saphenous vein (LSV). The LSV was reversed in 68 grafts and used in situ (that 
is, not reversed) in 69 grafts. This information was not recorded 70 grafts.
3.5.5 Graft Outcome and Operative Characteristics.
Of the grafts for which the case notes were reviewed (n=133), the mean follow up was 1093 days 
(median 843, range 12-4065). Of these 133 grafts, 33 (24.8%) occluded during the follow up period, 
at a mean time of 977 days (median 509, range 63-4065). Overall graft patency at 1, 3 and 5 years 
was 90%, 80% and 63%. This is shown in a survival curve in Figure 17.
Of the 33 grafts which occluded, 15 patients subsequently required amputation (45%), 18 did not 
(55%). Time to amputation was at a mean of 745 days (median 307, range 91-2428). One additional 
patient required amputation despite a functioning graft.
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Figure 17: Overall graft patency for infrainguinal grafts 1993-2003. Broken red lines indicate 1, 3 
and 5 year patency rates o f 90%, 80% and 63%, respectively.
Graft occlusion was associated with below knee anastomosis at the popliteal artery or the tibial 
vessels compared with above knee anastomosis (p=0.0007, RR=3.8 (1.6-9.2) Fisher’s exact test) and 
with in situ grafting compared with reversed vein grafting (p=0.025, RR=2.1 (1.1-4.0) Fisher’s exact 
test). It is worth noting, however, that in the majority of distal grafts (i.e. to below knee popliteal 
artery or tibial vessels), the LSV was used in situ. The reason for this is that in situ grafting allows 
better matching of the diameter of the anastomoses. The proximal anastomosis site did not influence 
graft occlusion (p=0.77, RR= 0.89 (0.4-2.0) Fisher’s exact test). These data are shown in Table 14.
The relative risk of amputation of the lower limb was not significantly affected by proximal or distal 
anastomosis site or reversal or in situ placement of the vein graft. However, the numbers of patients 
in this group was small and it is likely that the current data is insufficient to make this conclusion. 
These data are shown in Table 15.
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Graft
Occluded
Graft
Working P
RR
(95%CI)
Proximal
Anastomosis
CFA 27 82
0.77 0.89
(0.4-2.0)ABG/EIA 5 13
Distal
Anastomosis
Below
knee
27 47
0.0007 3.80 
(1.6-9.2)Above
knee
5 47
Long
Saphenous
Vein
In situ 23 42
0.025 2.1 
(1.1-4.0)Reversed 10 49
Table 14: Graft occlusion and its association with anastomosis site and vein use. Statistical analysis 
using Fishers exact test. CFA= Common Femoral Artery, ABG/EIA= Aortic Bifurcation Graft /  
External Iliac Artery.
Not
Amputated
Amputated P RR(95%CI)
Proximal
Anastomosis
CFA 15 12
1.0 0.93
(0.42-2.0)ABG/EIA 3 2
Distal
Anastomosis
Below
knee
14 14
0.11 0.5
(0.3-0.7)Above
knee
4 0
Long
Saphenous
Vein
In situ 13 10
1.0 1.13
(0.5-2.3)Reversed 5 5
Table 15: Amputation and its association with anastomosis site and vein use. Statistical analysis 
using Fishers exact test. CFA^ Common Femoral Artery, ABG/EIA= Aortic Bifurcation Graft /  
External Iliac Artery.
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3.5.6 Graft Occlusion and Patient Characteristics
Patient factors that may influence graft occlusion include gender, diabetes and smoking status. 
Univariate analysis of graft occlusion and patient factors was performed using Fishers exact test. 
Female gender showed a trend approaching, but not reaching, statistical significance as a factor 
which was associated with increased graft occlusion (Relative Risk (RR) 1.7 (95% Cl, 0.95-3.0), 
p=0.098). Diabetes and smoking were not associated with graft occlusion. This data is shown in 
Table 16 below.
Graft
Occluded
Graft
Working P
RR
(95%CI)
Gender Female 17 33
0.098 1.7
(0.95-3.0)Male 16 64
Diabetes YES 8 29
0.51 0.77
(0.38-1.5)NO 25 68
Smoker pre 
or post-op
YES 57 18
0.29 1.14
(0.9-1.5)NO 28 14
Table 16: Graft occlusion and its association with patient factors: gender, diabetes and smoking. 
Statistical analysis using Fishers exact test.
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3.5.7 Graft Occlusion and Medication Use
Medication use may influence graft occlusion. The use of antiplatelet agents, warfarin and statins 
were recorded as either present or absent at the time of surgery and also at the final follow up. Data 
for the final follow up period was less often available in the case notes.
Univariate analysis of graft occlusion and medication use was performed using Fishers exact test. 
Warfarin prescription was found to be associated with an increased risk of graft occlusion. This is 
likely to be due to the fact that warfarin is only used in patients with a very high risk of occlusion, 
such as history of previous graft thrombosis, poor blood flow through the graft and extensive distal 
disease. Antiplatelet and statin use did not appear to influence graft occlusion. These data and their 
analyses by Fisher’s exact test are shown in Tables 17, 18, and 19 below.
Graft
Occluded
Graft
Working
p RR
(95%CI)
Warfarin
pre-op
NO 29 94
0.10 0.39
(0.2-0.86)YES 3 2
Warfarin
post-op
NO 23 78
0.03 0.46(0.25-0.8)YES 8 8
Warfarin pre 
or post-op
NO 22 77
0.02 0.44
(0.25-0.8)YES 9 9
Table 17: Warfarin use and graft occlusion. Statistical analysis using Fisher’s exact test.
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Graft
Occluded
Graft
Working P
RR
(95%CI)
Antiplatelet
pre-op
YES 14 53
0.31 0.70 
(0.4-1.3)NO 18 42
Antiplatelet
post-op
YES 20 66
0.24 0.68
(0.4-1.3NO 11 21
Antiplatelet 
pre or post­
op
YES 23 74
0.58 0.58 
(0.4-1.7)NO 6 14
Table 18: Antiplatelet use and graft occlusion. Statistical analysis using Fisher’s exact test.
Graft
Occluded
Graft
Working P
RR
(95%CI)
Statin
pre-op
YES 2 12
0.52 0.54
(0.14-2.0)NO 30 83
Statin
post-op
YES 5 24
0.22 0.55
(0.23-1.3)NO 25 55
Statin pre or 
post-op
YES 5 24
0.22 0.56
(0.24-1.3)NO 24 54
Table 19: Statin use and graft occlusion. Statistical analysis using Fisher’s exact test.
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3.5.8 Analysis of Graft Occlusion by Survival Curves
The influence of patient characteristics (gender, diabetes and smoking) as well as medication use 
(statins, antiplatelets and warfarin) on time to graft occlusion were calculated and compared using 
the Logrank test. Kaplan-Meier survival curves were generated and are shown below in figures 18- 
23. Only statin use showed a trend approaching, but not reaching, statistical significance as a factor 
which was associated with decreased graft occlusion.
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Figure 18: Survival curves for graft occlusion and gender using Logrank test, p^O.84.
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Figure 19: Survival curves for gpaft occlusion and diabetes using Logrank test, p=0.77.
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Figure 20: Survival curves for graft occlusion and smoking history using Logrank test, p=0.55.
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Figure 21: Survival curves for graft occlusion and statin use post-operatively using Logrank test,
p=0.08.
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Figure 22: Survival curves for graft occlusion and antiplatelet use post-operatively using Logrank 
test, p=0.99.
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Figure 23: Survival curves for graft occlusion and warfarin use post-operatively using Logrank test, 
p=0,48.
1 0 0
3.5.9 Analysis of Amputation by Survival Curves
The influence of patient characteristics (gender, diabetes and smoking) as well as medication use 
(statins, antiplatelets and warfarin) on time to amputation were calculated and compared using the 
Logrank test. Kaplan-Meier survival curves were generated and are shown below in figures 24-29. 
So few amputations were performed on the study group that only trends of possible differences may 
be seen in this data. It is notable, however, that no patient prescribed a statin post-operatively 
subsequently underwent amputation.
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Figure 24: Survival curves for amputation and gender compared using Logrank test, p=0.33
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Figure 25: Survival curves for amputation and diabetes compared using Logrank test, p~O.Sl
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Figure 26: Survival curves for amputation and smoking post-operatively compared using Logrank 
test, p=0.66 .
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Figure 27: Survival curves for amputation and statin use post-operatively compared using Logrank 
test, p=0.001.
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Figure 28: Survival curves for amputation and antiplatelet use post-operatively compared using 
Logrank test, p=0.12.
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Figure 29: Survival curves for amputation and warfarin use post-operatively using Logrank test, 
p —0.25.
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3.5.10 Multivariate Analysis of Graft Occlusion
The effect of patient characteristics (gender, age, diabetes and smoking) as well as medication use 
(statin, antiplatelet and warfarin) on graft occlusion were analysed in a multivariate model to 
investigate which of the covariates influenced graft occlusion. These factors were analysed in a 
forward logistic regression model. Female gender and warfarin prescription were independent 
predictors of graft occlusion. This is shown in Table 20 below.
B S.E Wald df Sig Exp(B)
95%CIforExp(B))
Lower Upper
Age -0.02 0.024 0.677 1 0.410 0.980 0.934 1.028
Female -1.134 0.482 5.541 1 0.019 0.322 0.125 0.827
Antiplatelet -0.394 0.534 0.545 1 0.46 0.674 0.237 1.919
Warfarin -1.658 0.639 6.742 1 0.009 0.190 0.054 0.666
Statin 0.866 0.602 2.070 1 0.150 2.379 0.731 7.744
Smoker -0.235 0.477 0.242 1 0.623 0.791 0.311 2.014
Diabetic 0.419 0.502 0.695 1 0.405 1.520 0.568 4.070
Table 20: Multivariate analysis o f graft occlusion using logistic regression model. B=logistic 
regression coefficient, S.E = standard error ofB; Wald = Wald statistic; df=  degrees o f freedom; 
Sig = statistical significance; Exp(B)= Hazard Ratio.
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3.5.11 Secondary Operations
Of the 133 grafts for which the case notes were reviewed, 33 underwent secondary operations at a 
median time of 230 days (range 3-2592) from the initial operation. Of these, 9 grafts underwent 2 
secondary operations and one graft underwent 3 secondary operations, giving a total of 44 secondary 
procedures. The majority (75%) of these secondary procedures were elective procedures, the 
remainder were emergency cases.
Twenty six people required secondary operations to repair a problem with the graft. Five of these 
people required 2 secondary procedures, giving a total of 31 secondary procedures on the grafts. The 
proximal anastomosis was revised in 17 grafts, 6 underwent revision of the mid-segment of the 
graft, 3 had the distal anastomosis revised, and 4 required emergency thrombectomy. Only one case 
of graft angioplasty was recorded formally in the case notes but it is likely that more patients 
underwent this procedure without a record being made in the case notes. Of these 31 secondary 
procedures, 26 (84%) had a recorded abnormality on the surveillance scan which prompted re­
operation. One graft had a recognised problem which was not corrected and subsequently developed 
thrombosis of the graft requiring emergency thrombectomy. Two grafts did not appear to have any 
initial surveillance scans after the primary operation. These grafts required secondary operations at 
462 and 236 days. How the problem with these grafts was identified is not clear but will likely have 
been following clinical examination.
Not all of the secondary operations were to revise a problem with the original graft. Three grafts 
were re-done with PTFE after the vein graft had occluded, one patient required an axillo-bifemoral 
graft, three patients required ilio-femoral grafting and one patient required a femero-femero
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crossover graft for proximal disease. Four further patients underwent extension of the graft distally 
for progression of distal disease.
Additionally, 19 grafts had a problem identified at scanning which was not acted upon. The fate of 
these grafts was as follows: 11 continued to function normally until the final observation, 7 occluded 
but did not require amputation and 1 occluded requiring amputation. It is worth noting, however, 
that a further 21 grafts had a problem identified at scanning but these notes have been destroyed. 
Another 4 grafts had recorded problems but the notes have still to be seen. As such, information 
regarding possible secondary operations for these grafts are missing.
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3.5.12 Discussion of Audit Findings
Within the time frame of this research project and with difficulties in obtaining case records, I was 
unable to review the case notes for all 207 grafts. Of the case records that were reviewed, many 
were incomplete or contained sparse amounts of information. This was especially true with regard to 
drug prescription and smoking status. As such, the results presented here may only suggest trends of 
observations.
Within the ten-year period of this audit, 207 infrainguinal vein grafts were created for occlusive 
arterial disease. The number of grafts performed per year did not change significantly over this time 
period. There have been recent reports that the number of infrainguinal grafts performed per year in 
the UK is falling. This is thought to be due to more widespread use of angioplasty. Our findings do 
not follow this trend, however. Reasons for this include the fact that infrainguinal grafting, in our 
unit, has almost always been reserved for patients with critical limb ischaemia which is not usually 
amenable to angioplasty. The reduction in infrainguinal grafting reported by other groups is likely to 
represent a reduction in the number of grafts performed for claudication rather than a reduction in 
the number performed for critical limb ischaemia.
Patients undergoing infrainguinal grafting had a high incidence of concurrent medical conditions. 
This was expected in this population group since patients with peripheral vascular disease have an 
increased risk of cardiovascular morbidity and mortality. Only 3% of the patients had a diagnosis of 
hypercholesterolaemia at the time of surgery, however. This is likely to be due to the fact that few 
patients underwent cholesterol measurements at that time. The importance of hypercholesterolaemia 
in atherosclerosis has been recognised only relatively recently. This may also explain why few 
patients were prescribed a statin either at the time of infrainguinal bypass or post operatively.
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On univariate analysis, graft occlusion was associated with distal anastomosis (below the knee joint 
level) and in situ use of the long saphenous vein. Previous studies have also showed an association 
between distal grafting and graft occlusion but the association with in situ grafting is not a 
recognised factor. If the data are examined further, it is clear that the majority of distal grafts had in 
situ use of the long saphenous vein. This is to ensure that the anastomoses are better matched with 
respect to diameter of the vessels. It is extremely likely that this accounts for the apparent difference 
in patency rates between in situ and reversed grafts.
The expected effect of gender on infrainguinal graft patency rates is unclear. Initial studies 
suggested that female gender was a risk factor for graft occlusion but not all subsequent studies have 
supported this (145-148). Another feature is that females tend to come to infrainguinal bypass 
surgery at an older age than men, perhaps due to the protective effects of oestrogen. This difference 
in age at the time of surgery may influence graft patency rate (149). In the current study, univariate 
analysis of graft occlusion with respect to gender showed no statistically significant difference 
between males and females. However, the multivariate model did identify female gender as an 
independent predictor of graft occlusion. Furthermore, although there was a statistically significant 
difference in the age at operation between males and females (median age (range) of females = 
70.5yrs (38-91), median age (range) of males = 66.5yrs (42-86), p=0.0029, Mann Whitney test) in 
the current study, age was not an independent predictor of graft occlusion in the multivariate model. 
One possible reason for decreased graft patency in females is that they have smaller blood vessels -  
both arteries and veins. This causes technical difficulty at the time of operative intervention but also 
means that subsequent graft occlusion is an increased risk due to decreased diameter of run-off 
vessels and decreased anastomosis diameter (150).
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The role of diabetes with regard to the risk of graft occlusion is equally unclear. It is accepted that 
diabetic patients have poorer overall survival following surgical intervention mainly due to 
increased cardiac risk. This is reflected in their higher postoperative mortality and 5 year mortality 
compared with non-diabetics (150; 151). Furthermore, some studies suggest that diabetic patients 
have an increased risk of graft occlusion but this is not a consistent finding (145;152;153). 
Univariate and multivariate analysis of the current study shows no significant difference in graft 
patency rates between diabetics and non-diabetics.
Smoking is a major risk factor with regard to the development and progression of peripheral arterial 
disease (154). Continued smoking following infrainguinal bypass grafting is generally accepted as 
being detrimental to graft patency rates (I55;156). A recent meta-analysis of the effect of smoking 
on graft patency showed a 3 fold increased risk of graft occlusion (157). The current study, however, 
shows no association between smoking and graft occlusion. This probably reflects the retrospective 
nature of this study as patients often claim to have stopped smoking at both pre and post-operative 
clinic visits.
In investigating the relationship between drug prescription and graft outcome, statin use was weakly 
associated with improved graft patency and warfarin prescription was associated with increased 
graft occlusion. The findings with regard to warfarin prescription are very likely to be directly due to 
patients being prescribed warfarin as a last resort to try to maintain graft patency. Unfortunately, this 
information was not recorded in the case notes to allow this to be said with certainty. With regard to 
the association of statins with improved graft patency, this is in keeping with two recent studies 
showing similar effects (98;99). Henke et al investigated 338 infirainguinal grafts (both autogenous 
vein and synthetic grafts) and found an association between improved graft patency and lower 
amputation rate in patients taking statins. Abbruzzese et al investigated 189 autogenous vein grafts
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followed up for two years and found statin therapy to be associated with improved secondary graft 
patency. Neither of these two papers has sought to explain the mechanism of action of statins in 
improving graft patency. However, total cholesterol levels were noted to be no different between the 
groups studied at the time of surgery. This suggests that the action of statins was independent of the 
cholesterol lowering effects.
The Scottish Intercollegiate Guidelines Network (SIGN) guidelines for the management of patients 
with peripheral arterial disease were revised in October 2006. In light of recent evidence supporting 
the use of statins for patients with hypercholesterolaemia and a prior history of cardiovascular 
disease, statin therapy is now recommended for all patients with peripheral arterial disease and a 
cholesterol of >3.5mmol/l. The guidelines also recognise that statins may confer possible symptom 
improvement for patients with claudication and state this as a further reason for treating patients 
with peripheral arterial disease with a statin as first line therapy. No assessment has been made of 
recent studies which suggest that statin therapy may improve infrainguinal graft patency, however.
Given that there were relatively few amputations performed on the study population, it is difficult to 
associate this with drug prescription and smoking. Despite this, it is interesting that no patients who 
were recorded to be taking a statin required amputation. Further work would be required to clarify 
this apparent association.
The majority of secondary operations were to repair a specific problem with the graft whilst the 
remainder were to correct either the inflow or outflow of the graft, or to replace the graft with a 
synthetic conduit. Of the secondary operations on the grafts, only one angioplasty was recorded 
successfully in the case notes. From my experience working in the unit, it is extremely likely that
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other patients also underwent angioplasty but that no record appeared in the notes. Of the other 
procedures on the grafts, the majority (84%) were prompted by abnormal scans.
However, some grafts had abnormal scans which were not acted upon. Why this was the case is not 
clear. It is possible that some grafts were felt to have clinically insignificant scan abnormalities and 
were deliberately left without a secondary operation. It is also possible that some grafts were 
identified as requiring a secondary procedure but occluded before revision could be undertaken. 
Finally, it is also possible that the patient was felt to be medically unfit to undergo revisional surgery 
as this often requires prolonged general anaesthesia. The majority of grafts in which an abnormality 
was identified but no surgery was performed and then occluded, did not require an amputation. This 
is an important finding and may indicate that a conscious clinical decision was made not to operate 
on the failing graft.
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Chapter 4
GENERAL DISCUSSION
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4. General Discussion
The major aim of the experimental study was to establish whether prolonged hypoxia in the long 
saphenous vein predisposed the vein to develop intimai hyperplasia. In order to answer this 
question, the patients involved in the study had to be chosen carefully. It was important that the two 
patient groups were closely matched with regard to age, sex distribution, smoking history and other 
illnesses. The only patients from whom an ischaemic long saphenous vein could be obtained reliably 
were those undergoing major lower limb amputation. For the corresponding, non-ischaemic group, 
there would have been an abundance of long saphenous vein available from patients undergoing 
varicose vein surgery, however, these patients would have been much younger and would not have 
had similar medical histories to the amputees. As such, the patient group that was chosen to provide 
non-ischaemic vein tissue were those patients undergoing coronary artery bypass grafting. These 
patients were well matched with regard to age, sex, smoking history, diabetes and number of 
medications prescribed. The one factor which was seen to be different between the patient groups 
was statin prescription. The patients undergoing lower limb amputation were significantly less likely 
to be taking a statin compared with the patients undergoing coronary artery bypass grafting. This is 
an important clinical finding which may reflect the relative lack of understanding of the systemic 
nature of peripheral arterial disease amongst medical practitioners.
Patients with peripheral arterial disease have a three-fold increased risk of cardiovascular mortality 
compared with age-matched controls. Statins are principally cholesterol-lowering drugs. They have 
been proven to reduce the cardiovascular event rate in patients with established cardiovascular 
disease as well as in patients who only have risk factors for cardiovascular disease, even at 
cholesterol levels which would be classed as normal. Current clinical guidelines call for the 
treatment of patients with risk factors for atherosclerotic disease with a statin, even at normal
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cholesterol levels. The new Scottish Intercollegiate Guidelines Network document for the treatment 
of patients with peripheral arterial disease also recommends treatment with a statin for patients with 
peripheral arterial disease and a cholesterol of >3.5mmol/L
Organ culture of long saphenous vein leading to intimai hyperplasia has been validated as a suitable 
model of intimai hyperplasia. Although the numbers studied in this thesis were low, veins from the 
ischaemic limbs appeared to develop significantly more intimai growth compared with veins from 
the non-ischaemic limbs. This suggests that the ischaemic conditions prior to organ culture affected 
the vein in such a way as to predispose it to developing intimai hyperplasia. Possible mechanisms 
include activation of the mitogen activated protein kinase (MAP Kinase) p38 stress pathway. 
Activation of this pathway has been shown to cause vascular hypertrophy in patients with 
pulmonary vascular hypoxia leading to pulmonary hypertension. Another possible pathway which 
may be involved is the MAP Kinase p42/p44 pathway which leads to cellular proliferation and 
migration. Further work to assess the activity of these pathways in tissue from ischaemic and non- 
ischaemic veins would ascertain whether or not these pathways are upregulated in ischaemic vein 
tissue.
Addition of simvastatin to the organ culture model abolished the development of intimai hyperplasia 
in veins from ischaemic limbs. A similar effect was seen in the veins from the non-ischaemic limbs 
although the effect of simvastatin was less pronounced. The mechanism of action of simvastatin to 
inhibit the development of intimai hyperplasia is likely to be due to a combined inhibition of 
vascular smooth muscle cell (VSMC) proliferation and migration. This conclusion is based on the 
previous work of other authors as well as the findings in this thesis. Why there is a difference in the 
response of veins from ischaemic and non-ischaemic limbs is not clear. The statins may be 
inhibiting a pathway that is upregulated in the ischaemic veins. For example, the ischaemic veins
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may have accelerated levels of VSMC migration and proliferation which makes the tissue more 
susceptible to the effects of simvastatin. This effect may indicate a therapeutic target for simvastatin 
to prevent vein graft stenosis in patients undergoing both infrainguinal grafting for peripheral 
arterial disease and patients undergoing coronary artery bypass grafting.
Vascular smooth muscle cells which were explanted from the vein rings were grown on in cell 
culture and used in proliferation and migration assays. In the cell proliferation assay, simvastatin 
was seen to dose-dependently reduce the amount of VSMC proliferation. The preceding organ 
culture experiments had shown that the ischaemic tissue was more susceptible to the effects of 
simvastatin than the non-ischaemic tissue. There was no difference, however, in the mean 50% 
inhibitory concentrations of simvastatin for the VSMCs from both the ischaemic and non-ischaemic 
veins. This indicates that VSMCs explanted from both groups have an equivalent degree of 
susceptibility to the effects of simvastatin. Despite this, it is possible that the VSMCs from the 
ischaemic vein rings could be proliferating at a higher rate compared with those from the non- 
ischaemic veins. Further work which would clarify this would be to look at the VSMC proliferation 
rate between the two groups using growth curves. Additionally, it is worth considering the 
potentially different response of vascular smooth muscle cells once removed from the extracellular 
matrix of the vein ring. Techniques to study cell proliferation within whole vein rings such as using 
confocal microscopy could be used to further clarify this issue.
Addition of mevalonic acid to the cell proliferation experiments abolished the effect of simvastatin. 
This is evidence that the effect of the drug is via inhibition of intracellular production of mevalonic 
acid. Mevalonic acid is also a precursor of famesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP). These are lipid attachments necessary for the post translational modification 
of G proteins including ras, rho and rac. Which of these pathways are being inhibited by simvastatin
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could be investigated by the use of either FPP or GGPP instead of mevalonic acid in the cell culture 
experiments. Additionally, Western Blotting techniques could be used to look for reduced 
membrane or cytoplasmic localisation of these proteins in the presence of simvastatin to farther 
extrapolate its effects.
Migration of vascular smooth muscle cells was investigated using a modified Boyden chamber 
technique and showed that VSMC migration was enhanced in cells firom the ischaemic vein rings 
compared with cells fi-om the non-ischaemic vein rings. A possible mechanism that may explain this 
accelerated migration is the up-regulation of the MAP Kinase p38 system. This system has been 
shown to be up-regulated in response to hypoxia in pulmonary fibroblasts and cardiac myocytes, and 
could equally be up-regulated in VSMCs firom ischaemic vein tissue. The MAP Kinase p38 system 
is an intracellular signalling pathway which lies downstream of many processes including the 
activation of cell division cycle 42 (Cdc 42) and rac. These are two important systems which control 
cell migration and which are known to be stimulated by platelet derived growth factor (PDGF). 
Another possibility is that VSMCs firom the ischaemic vein rings have an increased expression of 
membrane PDGF receptors. It is known that PDGF cell membrane receptor expression is altered in 
response to autocrine factors such as transforming growth factor beta (TGF-p) and this may explain 
the enhanced migratory response of the VSMC fi*om the ischaemic vein group.
Simvastatin reduced the migration of vascular smooth muscle cells in these experiments although 
not to a statistically significant degree. It is likely that this represents a type II statistical error, as the 
numbers used in these experiments were small. Additionally, other authors have demonstrated an 
inhibition of VSMC migration in response to PDGF by simvastatin. The mechanism of action of 
simvastatin to inhibit VSMC migration is likely to be through the inhibition of membrane 
localisation of the G proteins, rho and rac. These control assembly and polymerisation of actin
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filaments in the leading edge of migrating cells. Both rho and rac require post-translational 
modification by the attachment of geranylgeranyl pyrophosphate (GGPP) in order that they may be 
functional in the cell membrane. GGPP is produced intracellularly by the mevalonate pathway 
which is directly inhibited by simvastatin.
Overall, the organ culture and cell culture experiments have demonstrated some important facts. 
Vein tissue from ischaemic limbs appears to be more susceptible to the development of intimai 
hyperplasia in organ culture compared with vein tissue from non-ischaemic limbs. This may be due 
to enhanced VSMC migration in cells from ischaemic vein rings compared with those from non- 
ischaemic vein rings. Furthermore, these findings may explain the relatively high rate of 
development of vein graft stenoses in patients undergoing infrainguinal bypass grafting for critical 
limb ischaemia. Additionally, simvastatin has been shown to inhibit the process of intimai 
hyperplasia in organ culture, this effect is likely to be due to a combined inhibition of VSMC 
migration and proliferation. This finding raises the possibility of using simvastatin therapeutically to 
prevent vein graft stenosis. The concentration of simvastatin used in these organ culture experiments 
was much higher than the serum levels of simvastatin attained at normal oral dosing, however. In 
order to attain the levels of simvastatin used in organ culture in vivo, novel delivery mechanisms of 
simvastatin could be employed. This could include the development of simvastatin-eluting sutures 
or bathing the vein in a simvastatin solution before anastomosing it as a bypass graft.
In auditing all infrainguinal bypass grafts performed in Glasgow Royal Infirmary between 1993- 
2003, a number of important observations were made. Firstly, the number of vein grafts performed 
each year during the observation period did not change. This reflects the fact that, in Glasgow Royal 
Infirmary, infrainguinal grafting is reserved for patients with critical limb ischaemia and the number 
of patients presenting with this condition each year has not changed. With an ageing population and
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a rise in the prevalence of diabetes, however, it is likely that more and more patients will present 
each year with critical limb ischaemia requiring surgery. It is therefore essential that these patients 
receive the best possible treatment and strategies aimed at prolonging graft patency are addressed.
Patients undergoing infrainguinal bypass grafting have a high rate of concurrent medical conditions. 
However, as in the amputees who were involved in the experimental study, few of these patients 
were prescribed a statin. This reflects the historic nature of the audit but it is imperative that this 
information is used in a positive manner and that all patients who undergo infrainguinal bypass 
grafting in future are assessed as to their cardiovascular risk and are placed on statin therapy 
accordingly. There should be very few patients who undergo bypass grafting that do not necessitate 
statin therapy.
Statin therapy was associated with improved graft patency and lower amputation rate in our data. 
This supports the findings of two recent studies which showed improved infrainguinal graft patency 
and limb salvage in patients taking statins. Neither study suggested a mechanism for the protective 
effect of simvastatin on infrainguinal vein grafts but it is likely to include reduced formation of 
intimai hyperplasia. This action is likely to be mediated through more than simple antiproliferative 
and anti-migratory effects that have been demonstrated in this study at a cellular and organ culture 
level. Indeed, as previously mentioned, the effects observed in the cell and organ culture 
experiments in this project were seen at much higher concentrations than can be achieved by normal 
oral administration of statins.
Within the multivariate model, female gender was associated with graft occlusion. This finding has 
been reported by previous studies but the reason for poorer graft outcome in females is unclear. 
Some studies have shown that females tend to undergo infrainguinal grafting at an older age than
119
males, perhaps due to later presentation of disease. In this study, age was not an independent factor 
with poorer graft outcome despite females being 4 years older than males at the time of operation. 
The reason for poorer graft patency rates among females is not clear but technical reasons including 
reduced vessel diameter are likely. Unfortunately, this detail was not available in this study but 
future studies should, ideally, include a measure of arterial and venous diameters.
In conclusion, long saphenous veins exposed to prolonged hypoxia develop an enhanced potential 
for the development of intimai hyperplasia in culture. This is likely to be mediated through various 
cell mechanisms including the stress response MAP Kinase p38 pathway. Simvastatin inhibits this 
process of intimai hyperplasia in organ culture and its effect is likely to be mediated through 
inhibition of cell proliferation and migration via a number of mechanisms but all principally related 
to the inhibition of famesylisation and geranylgeranlyation of essential G proteins including ras, rho 
and rac. In vivo, statins have been associated with improved graft patency as well as improved limb 
salvage in patients undergoing infrainguinal bypass grafting. This observation is likely to be due to a 
combination of factors but another therapeutic potential for the use of statins would be in local 
delivery to a vein graft in order to inhibit the formation of intimai hyperplasia.
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